Kraja, A. T., Liu, C., Fetterman, J. L., Graff, M., Have, C. T., Gu, C., ... North, K. E. (2019). Associations of Mitochondrial and Nuclear Mitochondrial Variants and Genes with Seven Metabolic Traits. *American Journal of Human Genetics, 104*(1), 112-138. https://doi.org/10.1016/j.ajhg.2018.12.001

Publisher's PDF, also known as Version of record

License (if available):
CC BY

Link to published version (if available):
10.1016/j.ajhg.2018.12.001

Link to publication record in Explore Bristol Research
PDF-document

This is the final published version of the article (version of record). It first appeared online via Elsevier at https://www.sciencedirect.com/science/article/pii/S000292971830452X. Please refer to any applicable terms of use of the publisher.

**University of Bristol - Explore Bristol Research**

**General rights**

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms
Mitochondria (MT), the major site of cellular energy production, are under dual genetic control by 37 mitochondrial DNA (mtDNA) genes and numerous nuclear genes (MT-nDNA). In the CHARGEmtDNA+ Consortium, we studied genetic associations of mtDNA and MT-nDNA associations with body mass index (BMI), waist-hip-ratio (WHR), glucose, insulin, HOMA-B, HOMA-IR, and HbA1c. This 45-cohort collaboration comprised 70,775 (insulin) to 170,202 (BMI) pan-ancestry individuals. Validation and imputation of mtDNA variants was followed by single-variant and gene-based association testing. We report two significant common variants, one in $MT-ATP6$ associated with BMI, and one in the D-loop with glucose. Five rare variants in $MT-ATP6$, $MT-ND5$, and $MT-ND6$ associated with BMI, WHR, or insulin. Gene-based meta-analysis identified $MT-ND3$ associated with BMI ($p < 1E-03$). We considered 2,282 MT-nDNA candidate gene associations compiled from online summary results for our traits (20 unique studies with 31 dataset consortia’s genome-wide associations (GWASs)). Of these, 109 genes associated ($p < 1E-06$) with at least 1 of our 7 traits. We assessed regulatory features of variants in the 109 genes, cis- and trans-gene expression regulation, and performed enrichment and protein-protein interactions analyses. Of the identified mtDNA and MT-nDNA genes, 79 associated with adipose measures, 49 with glucose/insulin, 13 with risk for type 2 diabetes, and 18 with cardiovascular disease, indicating for pleiotropic effects with health implications. Additionally, 21 genes related to cholesterol, suggesting additional important roles for the genes identified. Our results suggest that mtDNA and MT-nDNA genes and variants reported make important contributions to glucose and insulin metabolism, adipocyte regulation, diabetes, and cardiovascular disease.

**Introduction**

Mitochondria (MT) are double membrane organelles that generate the majority of cellular adenosine triphosphate (ATP) and metabolites and play a central role in human health. MT reside within cells and contain a separate maternally inherited $16.6$ kb circular mtDNA genome, consisting of 37 genes (Figure 1). The mtDNA encodes 13 core catalytic peptides that form the oxidative phosphorylation complexes (I, III-V) as well as the machinery needed...
to translate these peptides consisting of 22 transport RNAs (tRNAs) and 2 ribosomal RNAs (rRNAs). In addition, a noncoding sequence, known as the displacement loop (D-loop), encompasses the replication origin(s) and promoters for mtDNA.

MT function is also dependent upon many nuclear genes that encode proteins involved in mtDNA transcription, replication, cell apoptosis and mitophagy, nucleotide biosynthesis, metabolism, and iron and calcium homeostasis. Here we evaluate 2,282 candidate nuclear genes that also may contribute to MT function. We refer to these genes as “MT-nDNA candidates,” curated for this study based upon protein co-localization within the MT and text mining. Unlike mtDNA-encoded proteins that are transcribed and translated within MT, MT-nDNA genes are translated in the cytoplasm and their proteins are transported into MT through porins or complexes such as translocases.
The dual genomic origin (mtDNA and MT-nDNA) of MT components and the fact that mtDNA has a much higher mutation rate compared to the nuclear genome\textsuperscript{9,10} fuels our hypothesis that MT variants influence individual predisposition to complex diseases.\textsuperscript{1,12} Because of heteroplasmy, i.e., the coexistence of mutated and wild-type mtDNA in the same cell, mutations in mtDNA may not result in disease until the copy number of mtDNA carrying the mutation relative to the wild-type mtDNA in the relevant tissue(s) exceeds a threshold.\textsuperscript{13} The mtDNA copy number may serve as an indicator of MT function\textsuperscript{13} and various metabolic-related diseases, including cardiovascular disease (CVD).\textsuperscript{16–18} Studies have also shown that mitochondria have an important influence on multiple cardiovascular disease risk factors. For example, obesity impairs MT biogenesis.\textsuperscript{19–21} MT dysfunction has been also implicated in the development of insulin resistance.\textsuperscript{22–24}

Thus, our study prioritized obesity and insulin resistance pathways to CVD.

In our study we analyzed the dual genomic influence of MT function on seven important metabolic traits (body mass index [BMI], waist-hip ratio [WHR], fasting glucose, fasting insulin, HOMA-B, HOMA-IR, and HbA1c) as major risk factors of cardiovascular disease (CVD) in participants of the CHARGEmtDNA+ 45 participating cohorts. The mtDNA associations were evaluated at both the single nucleotide variant (SNV) and at the gene-based levels for rare alleles (minor allele frequency [MAF] < 1\%). The MT-nDNA candidates were studied for function, gene expression regulation, enrichment of pathways, and protein interactions. The overall goal was to illuminate MT-functioning and MT-disease causative variants.

Subjects and METHODS

CHARGE Cohorts

There were 45 participating cohorts with a total of 196,967 individuals (166,423 individuals were of the European [EA], 15,745 of African [AA], 1,567 of Asian [ASA], 11,307 of Hispanic/Latinos [HA], and 1,925 of Brazilian ancestry) who had at least one of the seven traits. CHARGE cohort summary descriptions are available online (see Supplemental Study Descriptions). The number of samples available from all cohorts differed by phenotype (Table S1). The resulting samples were smaller within each cohort when association tests were performed (by sub-setting individuals with genotyping available) to a total of 170,202 for BMI, 155,396 for WHR, 79,906K for fasting glucose, 70,778 for fasting insulin, 69,845 for HOMA-B, 69,926 HOMA-IR, and 101,218 for HbA1c. We use the acronym PA to refer to pan-ancestry. The procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and that proper informed consent was obtained.

Trait Harmonization

A total of seven traits were studied: BMI (kg/m\textsuperscript{2}), WHR (waist-hip ratio), fasting plasma glucose (mg/dL), fasting insulin (\muU/mL),
HOMA-B, HOMA-IR, and glycated hemoglobin (HbA1c, %) indicative of chronically elevated glucose levels. The homeostasis model assessment was based on plasma levels of fasting glucose and fasting insulin. HOMA-B is an indicator of beta-cell function calculated as HOMA-B = (360 × fasting insulin) / (fasting glucose – 60). HOMA-IR is an indicator of insulin resistance calculated as HOMA-IR = (fasting glucose × fasting insulin) / 405. Glucose and insulin measures were required to have been measured with a minimum fasting time of 8 hr; otherwise, the measure was set to missing. Each study was responsible for ensuring that each trait was normally distributed. Natural-log transformation was implemented for insulin, power transformation was performed when no other solutions were available, and inverse normal transformation was used as a last resort for BMI > 25 (details in the Supplemental Material and Methods, section 1). The association test analysis was restricted to non-diabetic participants when studying glycemic traits, by setting in the Supplemental Material and Methods, section 1). The association test analysis was restricted to non-diabetic participants when studying glycemic traits, by setting

\[
\text{trait} = \text{age} + \text{age}^2 + \text{sex} + \text{PCs} + \text{other study specific covariates (e.g., study center, etc)}
\]

Meta-Analysis Results

Figure 1. Graphical Presentation of Single mtDNA- and Gene-Based Association Meta-Analysis Results

Significant associations (trait, MT position, and p value) at liberal threshold (p ≤ 1E-03) are annotated with red arrows and gray text for single SNV associations and with green arrow for gene-based association, and text in red color represents SNVs that passed the threshold p ≤ 5E-04. The asterisk (*) marks missense or synonymous variants; a dagger (†) marks a SKAT gene-based significant association. The mtDNA is shown as one single molecule, by merging all genes from heavy and light MT strands. For visibility, gene colors rotate clockwise from first in blue in the D-loop to up to six coloring groups finishing in red at MT-ND1, and then recycling again from the first blue color at MT-ND1. The full information is summarized in Tables 1, 2, 3, and S2.a-S2.b. In blue text are shown bps-positions of 13 MT-coding genes (MT-ND1, MT-ND2, MT-CO1, MT-CO2, MT-ATP8, MT-ATP6, MT-CO3, MT-ND3, MT-ND4, MT-ND5, MT-ND6, MT-CYB), 2 MT-ribosomal RNAs (MT-RNR1 [12S RNA] and MT-RNR2 [16S RNA]), and 22 transport RNAs (MT-TE, TV, TL1, T1, TQ, TM, TW, TA, TN, TG, TY, TS1, TD, TK, TG, TR, TH, TS2, TL2, TE, TT, TP).

mtDNA Variant Harmonization

All mtDNA variants from each array (Table S14) were annotated to the nucleotide position according to the rCRS of the human mitochondrial DNA prior to analyses (see Web Resources). The probes used for each microarray were obtained from the manufacturer or dbSNP and aligned to the rCRS using Geneious 8.1. All probes were also submitted through the standard nucleotide basic local alignment search tool (BLAST) to ensure the probes bound with high specificity (> 90% identity) to the mitochondrial genome. In order to limit any potential binding to nuclear DNA segments, probes that bound to nuclear chromosomes with ≥ 80% matching were excluded from all analyses. The full lists of the validated mtDNA variants are available in the Supplemental Material and Methods, section 2 and Tables S15–S28.

mtDNA Imputation

The preparation of mtDNA data for imputation was done with PLINK. When preparing data for imputation, a few heterozygotes that may have existed in the mtDNA genotypes were set to missing via PLINK. The prephasing of mtDNA scaffold haplotypes at the cohort level was done with SHAPEIT2 for the full mtDNA (see Web Resources). SHAPEIT2 helped to have the mtDNA genotypes of a cohort in the right format to be used in the imputation pipeline with IMPUTE2. SHAPEIT2 was also used for QC checks, such as evaluating missingness in markers. In order to combine

The American Journal of Human Genetics 104, 112–138, January 3, 2019 115
analyses across different genotyping platforms, we performed imputation based on MT-1000G (see Supplemental Material and Methods, section 3). Imputations of mtDNA variants were implemented in IMPUTE2 at the cohort level in a window that included the full MT-chromosome (see Web Resources). Recoding of genotypetype probabilities into dosages was implemented via FCGENE (see Web Resources). Our reference MT-chromosome panel consisted of the 1000G data (PHASE 3, v.5) (see Web Resources). These data were based on sequence freeze and alignments, using only illumina platform sequences and only sequences with read lengths of 70 bps or greater. There were 3,617 mtDNA markers in 1000G. The 1000G included 2,504 individuals representing 26 sampled populations (the “Cosmopolitan” reference panel). In 1000G, there were 3,617 mtDNA markers of the 1000G data (PHASE 3, v.5) (see Web Resources). These cated from other future studies.

mtDNA. This is one more observation that the rare association rare variants are not in LD, but that does not have to hold for but in full LD, while they are rare. The typical assumption is that tion quality, given the rarity of mtDNA variants.

There were 3,617 mtDNA markers in 1000G. The 1000G included 2,504 individuals representing 26 sampled populations (the “Cosmopolitan” reference panel). After imputation, cohorts had differing number of SNVs, up to 3,832 SNVs for BMI, 3,829 for WHR, 3,809 for glucose, 3,801 for insulin, 3,801 for HOMA-B, 3,801 for HOMA-IR, and up to 3,744 for HbA1c. Although the imputation quality was good for most of cohorts (see imputation accuracy in Table S14), a great number of the SNVs were filtered for INFO (imputation quality) < 0.30, monomorphic or very rare (MAF < 0.0001) at the cohort level before association tests. Other QC were genotype call per cell had to be p ≥ 0.90, a marker was dropped if its missing rate was >0.05 and MAC had to be ≥5, (which if it was autosomal could have corresponded to MAC ≥10). The MAC was calculated for haplotypes as MAPN. (See Supplemental Material and Methods, section 3 for a more detailed methodology.) After mtDNA imputation, before performing statistical associations, we set any hetero-plasmic mutations to missing at the cohort level data. Details of QC via R Package: EasyQC (V10.0) (see Web Resources) and our internal programs and of the imputation steps can be found in the Supplemental Material and Methods, section 3. All filters implemented at the cohort level created non-uniform contributions of all cohorts in the meta-analysis. Many of the mtDNA variants were rare and per trait meta-analyses QQ-plots often showed an underestimation compared to expected association results (Figures S1–S7). The rarity of alleles was accompanied with lower quality of imputation and accordingly many of them were removed before any meta-analysis. Most studies had good imputation quality, given the rarity of mtDNA variants.

Variants MT-14272 and MT-14584 are opposite C/T versus T/C, but in full LD, while they are rare. The typical assumption is that rare variants are not in LD, but that does not have to hold for mtDNA. This is one more observation that the rare association findings in this study represent potential associations, until replicated from other future studies.

**mtDNA Association Statistical Analyses**

An additive genetic model was applied in association analyses using both self-developed regression models (the linear or linear mixed models written in R programming) and the SKAT (the prep-Scores) function in seqMeta R package: seqMeta package: Meta-Analysis of Region-Based Tests of Rare DNA Variants approaches (see Web Resources). Familial and maternal correlation structures were accounted for in the analysis of family data. Details of statistical association models 1–4 are described in the Supplemental Material and Methods, section 4.

**mtDNA Meta-Analyses**

Single-variant fixed-effects meta-analyses were conducted with METAL, and gene-based associations were performed in seqMeta (details in the Supplemental Material and Methods, sections 5–7) (Tables 1, 2, 3, S2.a, S2.b, and S13). The average allele frequency from Meta is an average of allele frequencies for a particular marker as contributed from each study and weighted by each study’s sample size as follows: FreqWeighted = ∑k=1nwkfk/∑k=1nwk, where k represents the indexing of contributing studies, wk is the sample size (number of individuals) per study, and fk is the coded allele frequency for a particular marker from a particular study. Our working group conducted an internal permutation test using ARIC study mtDNA data and determined that 49 independent mitochondrial variants represented an estimate of the number of independent genetic effects for mtDNA. Thus, 49 was used as a denominator for producing the Bonferroni corrected p significance threshold ≤ 0.05/49 ≤ 1E–03, a threshold for common variants (MAF ≥ 1%), but possibly liberal for rare variants (MAF < 1%) (Table 1). Furthermore, we considered p ≤ 0.05/(49 × 7 traits) ≤ 1.5E–04 as a conservative threshold when accounting for seven traits tested. We settled for a Bonferroni-threshold p ≤ 0.05/(49 × 2 domains) ≤ 5E–04, because the traits within a domain adipose/obesity (BMI and WHR) and glucose metabolism (glucose, insulin, HOMA-B, HOMA-IR, and HbA1c) are correlated and represent two domains. Because mtDNA is a small genome, the distributions of mtDNA QQ-plots with the existing samples do not always behave similarly to those observed for larger nuclear GWASs. While mtDNA variants MAF ≥ 1% formed relatively good QQ-plot distributions, the rare variants (MAF < 1%) were sometimes distributed with some deviation in the start (bottom-left) of the QQ-plot, as a result of meta-results in very rare alleles. Thus, the quality control of mtDNA QQ-plots were implemented by filtering at different rare MAF levels. We concluded that with the existing mtDNA meta-analysis results, QQ-plots with MAF > 0.8% were acceptable. Thus, out of 23 SNVs nominally (p ≤ 1E–03) associated with 6 metabolic traits (Figure 1), by adding the filter of MAC ≥ 5 for each cohort, then 7 variants passed p ≤ 5E–04 Bonferroni threshold.

For the gene-based analysis, we used Burden tests which combine the contributions of rare genetic variants within a gene region. Such tests assume similar directionality and effect sizes for each variant. In contrast, the sequence kernel association test (SKAT) for unrelated or family-based studies is an efficient regression-based approach for rare genetic variant analysis. The meta-analyses were performed using seqMeta (see Web Resources). The gene-based Bonferroni p value was calculated as p ≤ 0.05/ (37 mtDNA genes) ≤ 1E–03.

**Identification of MT-nDNA Candidate Genes**

We established a list of 2,282 MT-nDNA candidate genes from three sources: (1) Mito Carta 2.0, (2) Literature Lab (Acumen Biotech), and (3) MitoMiner (4.0) (see also Supplemental Material and Methods, section 7). We used the two separate sets of human genes and mouse ortholog genes from MitoCarta. We used Literature Lab to perform a literature search and identified 36 terms based on MeSH mitochondria. From each of the 36 terms (Table S29), we selected only the upper quartile list of genes from a Log Probability Function - scoring distribution. Each term was tested for association in overlapping with genes in pathway analysis (Figure S15). We conditioned this list with only genes from human nomenclature and accepted only genes that had more than 15 abstracts cited per selected gene (see Supplemental Material and Methods section 7).

Using MitoMiner we identified additional MT-nDNA candidate genes. They were filtered with a MT-MitoMiner index ≥ 0.70,
### Table 1. mtDNA Variants Associated with BMI, WHR, Glucose, Insulin, HOMA-B, HOMA-IR, and HbA1c METAL Meta-Analysis Single-Variant Results

| No | Pos  | Gene           | Annotation | Meta-analysis Level Results Selected with MAF of Weighted Allele Average Frequency > 5E% and Passing Meta-p-Threshold | p   | Dir | Het-p | N     |
|----|------|----------------|------------|---------------------------------------------------------------------------------------------------------------|-----|-----|-------|-------|
| 1  | 8796 | MT-ATP6       | missense   | WHR A/G 0.9676 0.0295 0.9135 0.9974 0.0324 834 0.13 (0.04) 4.1E-04                                          |     |     |       |       |
| 2  | 16320| rs62581338 D-loop | T/C        | GLUC T/C 0.0158 0.0954 0.0028 0.2439 0.0158 301 0.05 -- 9.44E-02                                          |     |     |       |       |
| 3  | 14274| rs2853814      | MT-ND6     | BMI T/C 0.0035 0.0022 0.0012 0.0002 0.0002 17 0.33 (0.08) 6.49E-04                                          |     |     |       |       |
| 4  | 14353| rs2853814      | MT-ND6     | BMI T/C 0.0035 0.0022 0.0012 0.0002 0.0002 17 0.33 (0.08) 6.49E-04                                          |     |     |       |       |
| 5  | 14584| MT-ND6        |           |           |                                                                                                               |     |     |       |       |

**Abbreviations and definitions:** No. order number; Pos, position in dbSNP database; Freq, weighted allele frequency in dbSNP; MinFreq, minimum allele frequency for contributing cohorts; MaxFreq, maximum allele frequency for contributing cohorts; MAF, minor allele frequency; MAC, minor allele count, calculated as MAF^3; p value, from single variant regression analysis; Dir, direction sign of contributing cohort’s beta; Het-p, heterogeneity p value test from METAL; N, individuals’ sample contributing in a particular marker meta-analysis (all results are of Pan-Ancestry).

**and by selecting the terms “Known mitochondrial” and “Predicted mitochondrial.” In MitoMiner, we kept only genes that were present in human nomenclature. MitoMiner included also the mitochondrial originated genes, which were later removed to keep our MT-nDNA list only of nuclear origin. Finally, three additional genes were added from a publication on MT-defects associated with β-cell dysfunction in a T2D mouse.**

### MT-nDNA Candidate Genes Analysis

As a result of the above work, a list of 2,282 MT-nDNA candidate gene labels (Table S30) were used to identify any significant results from 20 GWAS papers full summary results for seven metabolic traits, representing 31 datasets (Tables 4, S4, and S6). For the adipose traits, the GWAS publication full summary results used were for BMI, for WHR, for insulin, and for HOMA-B and -IR, and the summary results data were retrieved from the GIANT Consortium archives (see Web Resources). For glucose metabolism we used the summary results of glucose, insulin, HOMA-B, and HOMA-IR. These summary results data were retrieved from MAGIC Consortium archives (see Web Resources). For HbA1c we used two resources.

The published GWASs have large sample sizes, with a BMI study having a maximum of 339K individuals, WHR having 320K, glucose and insulin having 52K and 45K, respectively, and HOMA-B and -IR having 46K, and HbA1c having 160K. Consequently, we obtained results for 109 MT-nDNA candidate genes, accompanied by 588 sentinel significant SNVs (one best per gene and trait combination, out of seven traits, Tables 4, S6, and S9).

To identify the 588 SNVs, a pre-specified selection process was followed. First, we downloaded the latest dbSNP of NCBI reference data (batch 150), and we assigned each SNV to a gene (pseudogenes excluded). The intergenic variants were assigned to the closest gene, up to half the distance between two genes. Then, we merged the 31 full-GWAS sets to the annotated dbSNP, thus each GWAS-SNP was assigned to a gene. Each summary result was merged with MT-nDNA gene labels (Table S30). The corresponding significant SNVs results, ones with the smallest p value, per gene and per trait, were accepted in the final list (p < 0.05 / (2,282 × 7) = 3.13E−06). After this selection, we also performed an analysis based on 1000 Genomes to identify the number of independent SNVs within a gene.

The analysis produced a mean of independent SNVs per gene of 59, median of 38, and with a maximum of two outliers 542 (WWOX [MIM: 605131]) and 499 (FHIT [MIM: 605131]). If it was a gene-based test, then a conservative threshold p ≤ 0.05 / (542 × 7) traits ≤ 1.3E−05 could have been used, which is larger than the threshold we used, p ≤ 1E−06. Furthermore, to compare whether our MT-nDNA genes pass the genome-wide threshold of p ≤ 5E−08, generally used in GWAS publications, we merged our gene data with all possible reported SNVs from the GWAS-Catalog (accessed 01.27.2018, Table S12 and presented findings in the Results and Discussion paragraphs).

### Annotation, Enrichment Analysis, and Gene Expression and Regulation

The mtDNA as well as MT-nDNA significant variants were annotated to NCBI Entrez Gene, GeneCards and UniProtKB; enrichment analyses were performed with MetaCore and Literature Lab; pathways with KEGG and Reactome; gene expression and regulation were assessed using
HaploReg, RegulomeDB, GTEx, and Human Protein Atlas; and protein interactions were assessed using STRING and NCBI summary of interactions from other databases (see Web Resources), with references to databases BIND, BioGRID, EcoCyc, HIV-1-human protein interaction data, and HPRD. Specifically, for GTEx gene expression eQTL analysis, the eSNVs were considered significant when the eSNV had a GTEx p < 1E−07 and was in high LD (r^2 ≥ 0.80) with the best eSNV of the target gene. Depending on r^2 ≥ 0.80 to 1, we called them similar to “lead” or “lead” eSNVs. Otherwise, if the LD r^2 was < 0.02 to the target gene’s best eSNV, we called them “secondary” eSNVs (Table S8). Details of the resources and the corresponding references are provided in the Supplemental Material and Methods, sections 8 and 9. We have cited throughout the manuscript the corresponding gene MIM number from the Online Mendelian Inheritance in Man (see Web Resources).

Results

We evaluated the associations of mtDNA variants with seven key metabolic traits in meta-analyses of 45 cohorts (with up to N~170,202). For details on the harmonization of the phenotypes and genotypes, see Material and Methods and Supplemental Material and Methods, sections 1–6. The Supplemental Study Descriptions and Table S1 with BMI mean and standard deviation values give a depiction of each contributing cohort in this study.

mtDNA Single-Variants Associations

Seven SNVs, two variants with average weighted MAF > 1% (Tables 1 and S2.a and Figures S1–S7) and five with MAF < 1% (Tables 1 and S2.b) displayed statistically significant evidence of association with six metabolic traits (Bonferroni threshold p ≤ 5E−04, see in Material and Methods: mtDNA Meta-Analyses). MT-8706 in MT-ATP6 (MIM: 516060) (see Web Resources), associated with WHR (with sample weighted average of cohorts’ MAF = 3.24%, p = 4.1E−04 and MT-16320 (rs62581338) of the D-loop (with sample weighted average of cohorts’ MAF = 1.58%, p = 7.6E−05) associated with fasting glucose. The five rare variants were MT-8896 (rs202120082, missense) in MT-ATP7E associated with WHR, MT-14124 in MT-ND5 (MIM: 516005) associated with fasting plasma insulin, MT-14272 in MT-ND6 (rs2853814 [MIM: 516006], missense) associated with BMI, MT-14353 in MT-ND6 associated with BMI, and MT-14584 in ND6 associated with BMI.

The evidence of association by cohort is reported in Tables S2.a, S2.b, and S3. Typically, the cohort with a large sample size displayed the strongest evidence of association. For example, the HCHS/SOL study contributed disproportionately to several mtDNA-trait associations (see in the Supplemental Study Descriptions, CHARGE mtDNA+ Study Description). Even further, for the MT-ATP6 (position 8706) association with WHR, the strongest association in HCHS/SOL was in those of Central/South American background (so more Native American ancestry as compared to African American ancestry, Tables S2.a and S3).

mtDNA Rare Variants Gene-Based Associations

The mitochondrial rare variants for gene-based analysis were mapped to the start and end positions of each gene from the NCBI Reference Sequence GenBank: NC_012920.1 (see Web Resources). The rare variant gene-based meta-analysis using SKAT did not yield any significant associations. In contrast, the Burden test yielded a significant association between rare variants in MT-ND3 and BMI (p = 1E−03, T < 0.05 including 82 SNVs). A forest plot representing the 82 SNVs and the overall MT-ND3-overall meta is shown in Figure S17. Several gene-HOMA-B, HbA1c, and BMI associations were suggestively significant employing both the SKAT and Burden approaches (MT-RNAs MT-TF [MIM: 590070], MT-TV [MIM: 590105], MT-TG [MIM: 590035, MT-TQ [MIM: 590030], and MT-RNR1 [MIM: 561000]; p ≤ 1E−02; Tables 2 and 3). A total of 131 (T5-test) and 123 (T1-test) low-frequency and/or rare variants contributed to T5-test and T1-test, respectively. We used two gene-based approaches, burden test and sequence kernel association test (SKAT), to evaluate the association between a gene and a phenotype. Burden tests access the cumulative effects of multiple variants by assuming that all variants have the same directionality in a genetic region. SKAT tests use a score-based variance component framework without assuming that all variants have the same directionality. Although the two methods are different, they all evaluate aggregate effects of multiple low-frequency and/or rare variants.
with a phenotype. A significant gene-test reflects an aggregate effect of multiple variants in the same area. If most variants in ND6 are not associated with the phenotype, the gene-based test might not be significant. Although statistical significance was not achieved, the association of MT-ND6 with BMI was suggestive in the burden (p = 0.06 [T5] and 0.04 [T1]) and SKAT (p = 0.15 [T5] and 0.13 [T1]) and was not associated with the phenotype, although statistically significant was not achieved, the association of MT-ND6 with BMI was suggestive in the burden (p = 0.06 [T5] and 0.04 [T1]) and SKAT (p = 0.15 [T5] and 0.13 [T1]).

### Identification of MT-nDNA Candidate Variants

#### Associated with Metabolic Traits

We identified 2,282 MT-nDNA candidate genes (see Material and Methods) and assessed their association from 20 GWASs with 31 datasets (Table S4). From the MT-nDNA candidate list, 109 genes reached statistical significance following correction for multiple testing (Bonferroni p < 1E−06) of which 46 were associated with BMI, 2 with extreme obesity, 26 with WHR, 18 with glucose, 7 with insulin, 1 with HOMA-B, 1 with HOMA-IR, and 20 with HbA1c, totaling 121 associations (Table 4). The use of additional SNVs belonging to the same 109 MT-nDNA genes, but now sourced from the GWAS catalog for the same 7 traits or any other traits, indicated that 84% (27% improvement) of MT-nDNA genes passed p ≤ 5E−08, while 16% remained at p ≤ 1E−06 without passing the p ≤ 5E−08 threshold. Of the MT-nDNA associations, GCK (MIM: 138079), MRPL33 (MIM: 610059), PPARG (MIM: 601487), SLC2A2 (MIM: 138160), AMBRA1 (MIM: 613559), NR1H3 (MIM: 602423), MITCH2 (MIM: 613221), IGF1 (MIM: 147440), and BCL2 (MIM: 151430) were associated with more than one trait (Figures 2, 3, S8, and S9). For example, the well-known GCK is a member of hexokinases that phosphorylates glucose to produce glucose-6-phosphate, the first step in most glucose metabolism pathways, and has pleiotropic effects (see Discussion).

### Enrichment Analysis of MT-nDNA Candidate Genes

The 109 MT-nDNA selected genes are candidates for MT function based on their protein localization in mitochondria, as well as from mining the published literature (Table S5). We used Literature Lab and MetaCore software and the corresponding databases to perform enrichment analyses, which provided information for MT-nDNA gene-label relations with terms, pathways, diseases, gene ontology processes, and clustering (see Supplemental Material and Methods, section 8 and Figure S10). When comparing the 109 MT-nDNA candidate genes versus the remaining 2,173 (2,282 − 109), the 109 set showed enrichment (p = 1.7E−12) for “Signal transduction, Neuropeptide signaling pathways,” which included, among others, POMC (MIM: 176830) and MC4R (MIM: 155541), while no such enrichment was found for the 2,173 set. Out of 109 MT-nDNA candidate genes, 21 of the significantly associated genes were functionally related with cholesterol (Table S6 and Figure S11), 13 with glucose and insulin, and 5 with adipose/obesity. Of the 109 MT-nDNA genes, 13 associated with the “Type 2 diabetes” term (Table S7) while 18 were associated with “Cardiovascular disease” term (Table S7). (For space limitation, a detailed enrichment analysis is provided in the Supplemental Material and Methods, section 8.)

### Table 3. Results of mtDNA Gene-Based Burden T1 and T5 Meta-Analysis Test (p ≤ 0.01)

| Trait       | Ancestry | T | Gene   | p     | Beta | SE  | cMAFUsed | nSNVs |
|-------------|----------|---|--------|-------|------|-----|----------|-------|
| BMI         | PA       | 0.05 | MT-ND3 | 1.0E−03 | 0.007 | 0.002 | 0.290    | 82    |
| BMI         | PA       | 0.05 | MT-TQ  | 2.0E−03 | 0.020 | 0.006 | 0.075    | 12    |
| BMI         | PA       | 0.05 | MT-CO2 | 5.0E−03 | 0.003 | 0.001 | 0.491    | 155   |
| HOMAB       | PA       | 0.01 | MT-TF  | 5.0E−03 | 0.038 | 0.014 | 0.022    | 5     |
| HOMAB       | PA       | 0.01 | MT-TV  | 6.0E−03 | 0.088 | 0.032 | 0.009    | 2     |
| HOMAB       | PA       | 0.05 | MT-RNR1| 7.0E−03 | 0.002 | 0.001 | 1.323    | 119   |
| HOMAIR      | EA       | 0.05 | MT-TG  | 7.0E−03 | 0.027 | 0.010 | 0.061    | 13    |
| HOMAB       | EA       | 0.05 | MT-ND3 | 7.0E−03 | 0.006 | 0.002 | 0.194    | 81    |
| HOMAB       | EA       | 0.05 | MT-TV  | 8.0E−03 | 0.031 | 0.011 | 0.078    | 6     |
| HOMAB       | EA       | 0.05 | MT-TQ  | 8.0E−03 | 0.018 | 0.007 | 0.064    | 12    |
| HOMAB       | EA       | 0.05 | MT-RNR1| 9.0E−03 | 0.002 | 0.001 | 1.287    | 120   |
| HOMAB       | EA       | 0.05 | MT-TF  | 9.0E−03 | 0.018 | 0.007 | 0.127    | 10    |
| HOMAB       | EA       | 0.05 | MT-TV  | 9.0E−03 | 0.030 | 0.011 | 0.079    | 6     |
| HOMAB       | EA       | 0.01 | MT-RNR1| 1.0E−02 | 0.003 | 0.001 | 0.292    | 61    |

Abbreviations and definitions: Trait, the trait used for a specific test; PA, Pan ancestry; EA, European ancestry; T, MAF-value threshold for selecting SNVs to be included in the gene-based-burden association test; Gene, gene name from mtDNA; p, p value from the gene-based burden test; the score test of the weighted sum of genotypes has the form of statistic, $T = \sum w_jU_j$, where w is a weight for SNV j and U j is the score statistic for SNV j; Beta and SE are result of regressing the trait on a weighted sum of genotypes; cMAFUsed, cumulative minor allele frequency; nSNVs, the number of SNVs used in the gene-based burden meta-analysis.
Table 4. GWAS Findings for Seven Traits (BMI, WHR, Glucose, Insulin, HOMA-B, HOMA-IR, HbA1c) for 109 MT-nDNA Candidate Genes

| No | SNV   | Chrom | Position | Role         | Gene                        | Full Gene Name (Cytogenetic Position) | BMI p   | OBESITY p | WHR p | GLUC p | INS p | HOMA-B p | HOMAIR p | HbA1c p |
|----|-------|-------|----------|--------------|----------------------------|---------------------------------------|---------|------------|-------|--------|-------|----------|----------|---------|
| 1  | rs622798 | 1     | 45549599 | upstream-2k  | AKR1A1                    | Aldo-Keto Reductase Family 1 Member A1 (1p34.1) | 8.56E−07 | −          | −     | −      | −     | −        | −        | −       |
| 2  | rs1280316 | 1     | 66843725 | Intronic     | WDR78                     | WD repeat domain 78 (1p31.3)          | 6.81E−07 | −          | −     | −      | −     | −        | −        | −       |
| 3  | rs1093013 | 1     | 75634658 | Intronic     | SLC4A5                    | Solute carrier family 44 member 5     | −       | −          | −     | −      | −     | −        | −        | −       |
| 4  | rs6428792 | 1     | 119114244| Intronic     | WARS2                     | Tryptophyl TRNA Synthetase 2, Mitochondrial (1p12) | −       | −          | −     | −      | −     | −        | −        | −       |
| 5  | rs2301453 | 1     | 172389027| Intronic     | DNM3                      | Dynamin 3 (1q24.3)                    | −       | −          | −     | −      | −     | −        | −        | −       |
| 6  | rs4844390 | 1     | 207761504| Intronic     | CD46                      | CD46 Molecule, Complement Regulatory Protein (1q32.2) | −       | −          | −     | −      | −     | −        | −        | −       |
| 7  | rs11118296| 1     | 219408638| Intronic     | LYPLAL1                   | Lysophospholipase Like 1 (1q41)       | −       | −          | −     | 3.00E−07| −     | −        | −        | −       |
| 8  | rs6713865 | 2     | 23676937 | Intronic     | KLHL29                    | Kelch like family member 29 (2p24.1) | −       | −          | −     | −      | −     | −        | −        | −       |
| 9  | rs934778  | 2     | 25166355 | Intronic     | POMC                      | Proopiomelanocortin (2p21.3)         | 7.15E−07 | −          | −     | −      | −     | −        | −        | −       |
| 10 | rs1107238 | 2     | 26235376 | Intronic     | HADHA                     | Hydroxacyl-CoA Dehydrogenase/3-Ketoacyl-CoA Hydratase (Tritfunctional Protein), Alpha Subunit (2p23.3) | 8.86E−07 | −          | −     | −      | −     | −        | −        | −       |
| 11 | rs13404446| 2     | 27296386 | Intronic     | TRIM54                    | Tripartite Motif Containing 54        | −       | −          | −     | 3.09E−09| −     | −        | −        | −       |
| 12 | rs4665965 | 2     | 27313513 | Intronic     | MPV17                     | MPV17, Mitochondrial Inner Membrane Protein (2p23.3) | −       | −          | −     | 1.83E−09| −     | −        | −        | −       |
| 13 | rs3736594 | 2     | 27772914 | Intronic     | MRPL33                    | Mitochondrial Ribosomal Protein L33    | −       | −          | −     | 3.02E−13| 4.67E−07| −        | −        | −       |
| 14 | rs4346434 | 2     | 43992607 | Intronic     | LRPPRC                    | Leucine Rich Pentatricopeptide Repeat Containing (2p21) | −       | −          | −     | 8.52E−08| −     | −        | −        | −       |
| 15 | rs16843390| 2     | 209655109| Intronic     | MAP2                      | Microtubule Associated Protein 2 (2q34) | −       | −          | −     | 3.32E−08| −     | −        | −        | −       |
| 16 | rs715     | 2     | 210678331| Intronic     | CPS1                      | Carbamoyl-Phosphate Synthase 1 (2q34) | 5.81E−07 | −          | −     | −      | −     | −        | −        | −       |
| 17 | rs933994  | 2     | 218785893| Intronic     | CYP27A1                   | Cytochrome P450 Family 27 Subfamily A Member 1 (2q35) | 8.65E−07 | −          | −     | −      | −     | −        | −        | −       |
| 18 | rs17036328| 3     | 12348985 | Intronic     | PPARG                     | Peroxisome Proliferator Activated Receptor Gamma (3p25.2) | 4.27E−07 | −          | −     | 3.59E−12| −     | −        | −        | −       |

(Continued on next page)
| No  | SNV   | Chrom | Position | Role    | Gene Full Gene Name (Cytogenetic Position) | BMI p | OBESITY p | WHR p | GLUC p | INS p | HOMA-B p | HOMAIR p | HbA1c p |
|-----|-------|-------|----------|---------|-------------------------------------------|-------|------------|-------|--------|-------|----------|----------|---------|
| 19  | rs3729931 | 3     | 12585017 | intron  | RAF1 Raf-1 Proto-Oncogene, Serine/Threonine Kinase (3p25.2) | –     | –          | –     | 3.60E–10 | –     | –        | –        | –       |
| 20  | rs11715915 | 3     | 49417897 | nc-transcript | AMT Aminomethyltransferase (3p21.31) | –     | –          | –     | 4.90E–08 | –     | –        | –        | –       |
| 21  | rs12489828 | 3     | 52532998 | intron  | NT5DC2 5’-Nucleotide Domain Containing 2 (3p21.1) | –     | –          | –     | 2.60E–10 | –     | –        | –        | –       |
| 22  | rs2365389 | 3     | 61250788 | intron  | FHT Fragile Histidine Triad (3p14.2) | 3.75E–15 | –          | –     | –      | –     | –        | –        | –       |
| 23  | rs332375 | 3     | 66377079 | intron  | SLC25A26 Solute Carrier Family 25 Member 26 (3p14.1) | –     | –          | –     | 7.33E–07 | –     | –        | –        | –       |
| 24  | rs1735536 | 3     | 128377770 | intron  | EFSEC Eukaryotic Elongation Factor, Selenocysteine-TRNA Specific (3q21.3) | 2.95E–10 | –          | –     | –      | –     | –        | –        | –       |
| 25  | rs9844666 | 3     | 136255374 | intron  | PCCB Propionyl-CoA Carboxylase Beta Subunit (3q22.3) | 7.22E–07 | –          | –     | –      | –     | –        | –        | –       |
| 26  | rs11924648 | 3     | 171000207 | intron  | SLC2A2 Solute Carrier Family 2 Member 2 (3q26.2) | –     | –          | –     | 1.02E–17 | –     | –        | –        | 4.05E–09 |
| 27  | rs10012946 | 4     | 6291623 | intron  | WFS1 Wolframin ER Transmembrane Glycoprotein (4p16.1) | –     | –          | –     | 4.17E–07 | –     | –        | –        | –       |
| 28  | rs10518406 | 4     | 122841742 | intron  | FG2 Fibroblast Growth Factor 2 (4q28.1) | 6.50E–07 | –          | –     | –      | –     | –        | –        | –       |
| 29  | rs1458758 | 4     | 122914724 | intron  | NUDT6 Nudix Hydrolase 6 (4q28.1) | –     | –          | –     | 6.22E–08 | –     | –        | –        | –       |
| 30  | rs303084 | 4     | 123145793 | intron  | SPATS5 Spermatogenesis associated 5 (4q28.1) | –     | –          | –     | 3.40E–07 | –     | –        | –        | –       |
| 31  | rs12654264 | 5     | 75352778 | intron  | HMGCR 3-Hydroxy-3-Methylglutaryl-CoA Reductase (5q13.3) | 1.81E–08 | –          | –     | –      | –     | –        | –        | –       |
| 32  | rs10478424 | 5     | 119453325 | intron  | HSD17B4 Hydroxysteroid 17-Beta Dehydrogenase 4 (5q23.1) | –     | –          | –     | 1.40E–07 | –     | –        | –        | –       |
| 33  | rs2881156 | 5     | 135812973 | intron  | SLC25A48 Solute carrier family 25 member 48 (5q31.1) | –     | –          | –     | 8.10E–07 | –     | –        | –        | –       |
| 34  | rs3828870 | 6     | 16743066 | intron  | ATXN1 Ataxin 1 (6p22.3) | –     | –          | –     | –      | –     | –        | –        | 5.52E–07 |
| 35  | rs1800562 | 6     | 26092913 | intron  | HFE Hemochromatosis (6p22.2) | –     | –          | –     | –      | –     | –        | –        | 4.67E–28 |
| 36  | rs1800626 | 6     | 31575254 | upstream-2KB | TNF Tumor necrosis factor (6p21.33) | –     | –          | –     | 7.30E–07 | –     | –        | –        | –       |
| 37  | rs6457796 | 6     | 34860776 | intron  | UHRF1BP1 UHRF1 binding protein 1 (6p21.31) | 1.15E–09 | –          | –     | –      | –     | –        | –        | –       |
| No | SNV       | Chrom | Position | Role               | Gene       | Full Gene Name (Cytogenetic Position) | BMI p | OBESITY p | WHR p | GLUC p | INS p | HOMA-B p | HOMAIR p | HbA1c p |
|----|-----------|-------|----------|--------------------|------------|---------------------------------------|-------|-----------|-------|--------|------|-----------|----------|---------|
| 38 | rs10434   | 6     | 43785475 | utr-3-prime       | VEGFA      | Vascular endothelial growth factor A (6p21.1) | –     | –         | –     | 8.80E–07 | –    | –         | –        | –       |
| 39 | rs1049354 | 6     | 88143732 | utr-3-prime       | CNR1       | Cannabinoid receptor 1 (6q15)           | 9.57E–07 | –         | –     | –      | –    | –         | –        | –       |
| 40 | rs9400239 | 6     | 108656460| intron             | FOXO3      | Forkhead box O3 (6q21)                 | 1.61E–08 | –         | –     | –      | –    | –         | –        | –       |
| 41 | rs1273733 | 6     | 121131419| downstream-500B   | TBC1D32    | TBC1 domain family member 32 (6q22.31)  | 3.96E–12 | –         | –     | –      | –    | –         | –        | –       |
| 42 | rs1049349 | 6     | 121449496| utr-3-prime       | GJA1       | Gap junction protein alpha 1; synonymous: CX43 (6q22.31) | 4.18E–15 | –         | –     | –      | –    | –         | –        | –       |
| 43 | rs1293954 | 6     | 151669826| intron             | ESR1       | Estrogen receptor 1 (6q25.1-q25.2)     | 4.41E–09 | –         | –     | –      | –    | –         | –        | –       |
| 44 | rs1203576 | 7     | 40808233 | intron             | SUGCT      | C7orf10 (Succinyl-CoA:Glutaryl-CoA Transferase, 7p14.1) | 1.48E–10 | –         | –     | –      | –    | –         | –        | –       |
| 45 | rs2908289 | 7     | 44184343 | intron             | GCK        | Glucokinase (7p13)                     | –     | 3.32E–08 | –     | 6.00E–09 | –    | 2.24E–19 | –        | –       |
| 46 | rs108867  | 7     | 44705214 | intron             | OGDH       | Oxoglutarate dehydrogenase (7p13)      | 7.90E–08 | –         | –     | –      | –    | –         | –        | –       |
| 47 | rs16892421| 8     | 106499705| intron             | OXR1       | Oxidation resistance 1 (8q23.1)        | –     | 6.94E–07 | –     | –      | –    | –         | –        | –       |
| 48 | rs7835803 | 8     | 120030213| intron             | DEPTOR     | DEP domain containing MTOR interacting protein (8q24.12) | –     | –         | –     | 4.97E–07 | –    | –         | –        | –       |
| 49 | rs2777795 | 9     | 104910084| intron             | ABCA1      | ATP binding cassette subfamily A member 1 (9q31.1) | –     | 3.13E–08 | –     | –      | –    | –         | –        | –       |
| 50 | rs7023913 | 9     | 128255683| downstream-500B   | DNM1       | Dynamin 1 (9q34.11)                    | –     | 7.30E–07 | –     | –      | –    | –         | –        | –       |
| 51 | rs3829109 | 9     | 136362314| intron             | DNLLZ      | DNL-Type Zinc Finger (9q34.3)          | –     | –         | –     | 1.13E–10 | –    | –         | –        | –       |
| 52 | rs1244497 | 10    | 7838019  | intron             | TAF3       | TATA-box binding protein associated factor 3 (10p14) | 1.84E–11 | –         | –     | –      | –    | –         | –        | –       |
| 53 | rs5030913 | 10    | 69246375 | intron             | HKDC1      | Hexokinase domain containing 1 (10q22.1) | –     | –         | –     | –      | –    | –         | –        | 3.56E–13 |
| 54 | rs4745982 | 10    | 69330087 | intron             | HK1        | Hexokinase 1 (10q22.1)                 | –     | –         | –     | –      | –    | –         | –        | 2.87E–65 |
| 55 | rs7899106 | 10    | 85651147 | intron             | GRID1      | Glutamate Ionotropic Receptor Delta Type Subunit 1 (10q23.2) | 2.96E–08 | –         | –     | –      | –    | –         | –        | –       |
| 56 | rs7917772 | 10    | 102727686| intron             | SFXN2      | Sideroflexin 2 (10q24.32)              | –     | 1.45E–09 | –     | –      | –    | –         | –        | –       |
| 57 | rs1004467 | 10    | 102834750| intron             | CYP17A1    | Cytochrome P450 Family 17 Subfamily A Member 1 (10q24.32) | 1.18E–07 | –         | –     | –      | –    | –         | –        | –       |

(Continued on next page)
| No | SNV | Chrom | Position | Role          | Gene                            | Full Gene Name (Cytogenetic Position) | BMI p | OBESITY p | WHR p | GLUC p | INS p | HOMA-B p | HOMAIR p | HbA1c p |
|----|-----|-------|----------|---------------|---------------------------------|--------------------------------------|-------|-----------|-------|--------|------|----------|----------|--------|
| 58 | rs3740390 | 10   | 102878723 | intron      | AS3MT                           | Arsenite Methyltransferase (10q24.32) | 4.82E−08 | –         | –     | –      | –    | –        | –        | –      |
| 59 | rs4758633 | 11   | 219538    | intron      | SIRT3                           | Sirtuin 3 (11p15.5)                  | –     | –         | –     | –      | –    | –        | –        | 3.44E−10 |
| 60 | rs757110  | 11   | 17396930  | missense    | ABCC8                           | ATP Binding Cassette Subfamily C Member 8 (11p15.1) | 4.23E−07 | –         | –     | –      | –    | –        | –        | –      |
| 61 | rs10767664 | 11  | 27704439  | intron      | BDNF                            | Brain Derived Neurotrophic Factor (11p14.1) | 5.53E−13 | –         | –     | –      | –    | –        | –        | –      |
| 62 | rs11038913 | 11  | 46538180  | intron      | AMBRA1                          | Autophagy and beclin 1 regulator 1 (11p11.2) | –     | –         | –     | 4.29E−08 | 4.91E−18 | –        | –        | –      |
| 63 | rs11039149 | 11  | 47255124  | intron      | NR1H3                           | Nuclear Receptor Subfamily 1 Group H Member 3 (11p11.2) | –     | –         | –     | 1.26E−12 | 4.13E−45 | –        | –        | –      |
| 64 | rs7118178  | 11   | 47637583  | intron      | MITCH2                          | Mitochondrial carrier 2 (11p11.2)   | 5.12E−08 | –         | –     | 3.84E−14 | 2.16E−29 | –        | –        | –      |
| 65 | rs4246215  | 11   | 61796827  | intron      | FEN1                            | Flap Structure-Specific Endonuclease 1 (11p12.2) | –     | –         | –     | 4.46E−11 | –    | –        | –        | –      |
| 66 | rs174556   | 11   | 61813163  | intron      | FADS1                           | Fatty acid desaturase 1 (11q12.2)   | –     | –         | –     | 7.82E−18 | –    | –        | –        | –      |
| 67 | rs7943191  | 11   | 62561079  | intron      | EE1G                            | Eukaryotic translation elongation factor 1 gamma (11q12.3) | –     | –         | –     | 4.36E−08 | –    | –        | –        | –      |
| 68 | rs11231150 | 11   | 62584330  | intron      | TUT1                            | Terminal uridylyl transferase 1, U6 snRNA-specific (11q12.3) | –     | –         | –     | 5.20E−08 | –    | –        | –        | –      |
| 69 | rs1017639  | 11   | 68831066  | intron      | CPT1A                           | Carnitine Palmitoyltransferase 1A (11q13.3) | 4.96E−10 | –         | –     | –      | –    | –        | –        | –      |
| 70 | rs1296252  | 11   | 83273268  | intron      | CCDC90B                         | Coiled-Coil Domain Containing 90B (11q13.3) | 7.60E−08 | –         | –     | –      | –    | –        | –        | –      |
| 71 | rs2110073  | 12   | 6966719   | intron      | PHB2                            | Prohibitin 2 (12p13.31)              | –     | –         | –     | –      | –    | –        | –        | 4.44E−08 |
| 72 | rs7311050  | 12   | 7013532   | intron      | LPCAT3                          | Lysophosphatidylcholine Acyltransferase 3 (12p13.31) | –     | –         | –     | –      | –    | –        | –        | 8.60E−08 |
| 73 | rs1049380  | 12   | 26336611  | downstream-500B                | ITPR2                            | Inositol 1,4,5-Trisphosphate Receptor Type 2 (12p11.23) | –     | –         | –     | 1.42E−13 | –    | –        | –        | –      |
| 74 | rs2408955  | 12   | 48105348  | upstream-2KB                   | PFKM                            | Phosphofructokinase, muscle (12q13.11) | –     | –         | –     | –      | –    | –        | –        | 1.42E−15 |
| 75 | rs35767    | 12   | 102481791 | missense   | IGF1                            | Insulin Like Growth Factor 1 (12q23.2) | –     | –         | –     | 7.27E−08 | 7.57E−08 | –        | –        | –      |
| 76 | rs4766578  | 12   | 111466567 | intron      | ATXN2                           | Ataxin 2 (12q24.12)                 | 2.85E−07 | –         | –     | –      | –    | –        | –        | 1.84E−07 |
| 77 | rs9581856  | 13   | 27451478  | upstream-2KB                   | MTIF3                           | Mitochondrial Translational Initiation Factor 3 (13q12.2) | 1.03E−08 | –         | –     | –      | –    | –        | –        | –      |

(Continued on next page)
| No | SNV    | Chrom | Position | Role     | Gene                          | Full Gene Name (Cyto genetic Position) | BMI p | OBESITY p | WHR p | GLUC p | INS p | HOMA-B p | HOMAIR p | HbA1c p |
|----|--------|-------|----------|----------|-------------------------------|----------------------------------------|-------|------------|-------|--------|-------|-----------|-----------|---------|
| 78 | rs1124607 | 13    | 27921083 | intron   | PDX1                          | Pancreatic And Duodenal Homeobox 1 (13q12.2) |      |            |       |        |       |           |           |         |
| 79 | rs1325363 | 13    | 3192439  | intron   | STARD13                        | STAR related lipid transfer domain containing 13 (13q13.1-q13.2) | 7.25E–08 |            |       |        |       |           |           |         |
| 80 | rs1078892 | 13    | 40563883 | intron   | FOXO1                          | Forkhead Box O1 (13q14.11) | 5.11E–08 |            |       |        |       |           |           |         |
| 81 | rs7143963 | 14    | 10238088 | intron   | TRAF3                          | TNF Receptor Associated Factor 3 | 2.82E–07 |            |       |        |       |           |           |         |
| 82 | rs1290847 | 15    | 98744146 | intron   | IGF1R                          | Insulin Like Growth Factor 1 Receptor |      |            |       |        |       |           |           |         |
| 83 | rs740862  | 16    | 3639677  | intron   | DNASE1                         | Deoxyribonuclease 1 | 3.21E–07 |            |       |        |       |           |           |         |
| 84 | rs151181  | 16    | 28479196 | intron   | CLN3                          | CLN3, Battenin                   | 2.10E–07 |            |       |        |       |           |           |         |
| 85 | rs805138  | 16    | 28880144 | intron   | ATP2A1                         | ATPase Sarcoplasmic/ Endoplasmic Reticulum Ca²⁺ Transporting 1 | 8.17E–17 |            |       |        |       |           |           |         |
| 86 | rs749767  | 16    | 3113086  | downstream-500B | BCKDK                 | Branched Chain Ketoacid Dehydrogenase Kinase | 1.21E–09 |            |       |        |       |           |           |         |
| 87 | rs7186084 | 16    | 68782357 | intron   | CDH1                          | Cadherin 1                       |      |            |       |        |       |           |           | 1.09E–07 |
| 88 | rs1847591 | 16    | 78908913 | intron   | WWOX                          | WW domain containing oxidoreductase |      |            |       |        |       |           |           |         |
| 89 | rs9904685 | 17    | 1352101  | intron   | YWHAE                         | Tyrosine 3-monooxygenase/ tryptophan 5-monooxygenase activation protein epsilon | 6.27E–07 |            |       |        |       |           |           |         |
| 90 | rs4646404 | 17    | 17516885 | intron   | PEMT                          | Phosphatidylethanolamine N-Methyltransferase |      |            |       |        |       |           |           |         |
| 91 | rs9914988 | 17    | 28856086 | intron   | ERAL1                         | Era like 12S mitochondrial tRNA chaperone 1 |      |            |       |        |       |           |           | 2.77E–11 |
| 92 | rs242559  | 17    | 45948522 | intron   | MAPT                          | Microtubule Associated Protein Tau |      |            |       |        |       |           |           |         |
| 93 | rs1319247 | 17    | 63106279 | intron   | TANC2                         | Etratricopeptide repeat, ankyrin repeat and coiled-coil containing 2 |      |            |       |        |       |           |           |         |
| 94 | rs12940622| 17    | 80641771 | intron   | RPTOR                         | Regulatory Associated Protein Of MTOR Complex 1 | 2.49E–09 |            |       |        |       |           |           |         |
| 95 | rs1044661 | 17    | 82943144 | intron   | B3GNT1/TBCD                   | UDP-GlcNAc:BetaGal Beta-1,3-N-Acetylglucosaminyltransferase Like 1/Tubulin Folding CofactorD |      |            |       |        |       |           |           | 1.74E–46 |
| 96 | rs1788785 | 18    | 23562376 | intron   | NPC1                          | NPC Intracellular Cholesterol Transporter 1 | 1.98E–08 |            |       |        |       |           |           |         |

(Continued on next page)
| No. | SNV        | Chrom | Position       | Role          | Gene                      | Full Gene Name (Cytogenetic Position) | BMI p   | OBESITY p | WHR p | GLUC p | INS p | HOMA-B p | HOMAIR p | HbA1c p |
|-----|------------|-------|----------------|---------------|---------------------------|-----------------------------------|--------|-----------|-------|--------|-------|----------|----------|---------|
| 97  | rs17066842 | 18    | upstream-2KB   | MC4R          | Melanocortin 4 Receptor   | 6.40E-14                         | –      | –         | –     | –      | –     | –        | –        | –       |
| 98  | rs12454712 | 18    | intron         | BCL2          | BCL2, Apoptosis Regulator | –                                 | –      | –         | 1.10E-09 | –      | 1.39E-07 | –        | –        | –       |
| 99  | rs757318   | 19    | intron         | CRTC1         | CREB Regulated Transcription Coactivator 1 | 8.76E-09                         | –      | –         | –     | –      | –     | –        | –        | –       |
| 100 | rs2075650  | 19    | intron         | TOMM40        | Translocase Of Outer Mitochondrial Membrane 40 | 1.25E-08                         | –      | –         | –     | –      | –     | –        | –        | –       |
| 101 | rs405509   | 19    | upstream-2 kb  | APOE          | Apolipoprotein E          | 2.65E-07                         | –      | –         | –     | –      | –     | –        | –        | –       |
| 102 | rs2281361  | 20    | intron         | TM9SF4        | Transmembrane 9 superfamily member 4 | 9.78E-07                         | –      | –         | –     | –      | –     | –        | –        | –       |
| 103 | rs878639   | 20    | intron         | UQCC1         | Ubiquinol-Cytochrome C Reductase Complex Assembly Factor 1 | –                                 | –      | 1.50E-11  | –     | –      | –     | –        | –        | –       |
| 104 | rs2076574  | 20    | intron         | TOP1          | DNA topoisomerase I       | 4.11E-07                         | –      | –         | –     | –      | –     | –        | –        | –       |
| 105 | rs5750373  | 22    | intron         | MPST          | Mercaptopyruvate Sulfurtransferase | –                                 | –      | –         | –     | –      | –     | –        | –        | 2.17E-07|
| 106 | rs2284099  | 22    | intron         | TSPO          | Translocator Protein      | 6.65E-07                         | –      | –         | –     | –      | –     | –        | –        | –       |
| 107 | rs1050828  | 23    | missense       | G6PD          | Glucose-6-phosphate dehydrogenase | –                                 | –      | –         | –     | –      | –     | –        | –        | 8.23E-135|
| 108 | rs1448032  | 23    | intron         | FUNDC2        | FUN14 domain containing 2 | –                                 | –      | –         | –     | –      | –     | –        | –        | 5.92E-17|
| 109 | rs5940514  | 23    | intron         | TMLHE         | Trimethyllysine hydroxylase, epsilon | –                                 | –      | –         | –     | –      | –     | –        | –        | 2.22E-19|

p values in italics annotate SNVs that associate as significant with more than one trait.
findings demonstrate the importance of several MT-nDNA candidates to cardiometabolic outcomes.

**eQTLs of MT-nDNA Candidate Variants**

Several variants in or near MT-nDNA candidate genes were identified as expression QTL (eSNV) (Table S8). Based on RegulomeDB,78 three variants were the best in eSNVs features' ranking. The first was rs242559, intronic to MAPT (MIM: 157140). Mutations in MAPT associate with lower mitochondrial nicotinamide adenine dinucleotide (NADH) levels,79 partially suppress complex I-driven respiration, and lower overall ATP production by oxidative phosphorylation, with cells relying on glycolysis to maintain ATP levels. The second, rs9897919, is a 3' UTR variant for TBCD (MIM: 604649), tubulin folding cofactor D, and B3GNTL1 (17q25.3 [MIM: 615337]), a putative glycosyltransferase. The third, rs1788821, is intronic to NPC1 (MIM: 607623), which is an intracellular cholesterol transporter with a role in the egress of cholesterol from the endosomal/lysosomal compartments (Table S9).

The findings of RegulomeDB were reinforced by HaploReg (v.4.1).80 The MT-nDNA variants showed an enrichment in transcription regulation features. For instance, rs242559 of MAPT is localized within the promoter histone marks in skeletal muscle, at enhancer histone marks of 16 tissues, and at DNase marks of 4 tissues. The second, rs9897919, is a 3' UTR variant for TBCD (MIM: 604649), tubulin folding cofactor D, and B3GNTL1 (17q25.3 [MIM: 615337]), a putative glycosyltransferase. The third, rs1788821, is intronic to NPC1 (MIM: 607623), which is an intracellular cholesterol transporter with a role in the egress of cholesterol from the endosomal/lysosomal compartments (Table S9).

To determine the eSNVs' gene targets in specific tissues, we used GTEx (v.7.0)81,82 with a summary in Table S8 and detailed in Table S10. The 42 unique eSNVs were assigned to 29 genes targeting regulation of 50 genes, distributed among 13 tissues (adipose, tibial artery, thyroid, skin, blood, brain, skeletal muscle, esophageal muscularis, fibroblast, liver, pancreas, testis, and tibial nerve). There were 28 unique lead and 18 unique secondary (LD $r^2$ was $< 0.02$ to the target gene's best eSNV) eSNVs identified (see Material and Methods). For example, rs2510344 of NPC1 regulates C18orf8 in skin and rs11663558 of NPC1 regulates its own NPC1 gene expressed highest in subcutaneous adipose tissue (GTEx data).

**trans-eQTLs of MT-nDNA Candidate Variants**

We combined the GWAS p value for the MT-nDNA SNVs with additional evidence from trans-gene expression regulation for a specific variant using GWAS3D83 (Figures S12.1–S12.3). The GWAS3D software selected 16 cell types, which included chromosomal looping data (SC or ChIA-PET or Hi-C) and important transcriptional marker data (H3K4me1, H3K27ac, DHSs, EP300, and CTCF).83 Among several trans-eQTLs, for example, rs2881156 ($p = 8.1 \times 10^{-7}$) of SLC25A48 (5q31.1 [MIM: 616150], Figure S12.1) associated with obesity and trans-regulated expression of three genes: SAR1B (5q31.1 [MIM: 607690]) involved in protein transport from the endoplasmic reticulum to the Golgi (mutations in this gene are a cause of chylomicron retention disease [MIM: 246700]);84 TRPC7 (5q31.1), a regulator of intracellular calcium levels;85 and REEP2 (5q31.2 [MIM: 609347]), which enhances the function of sweet taste receptors86 and is about 80 times higher expressed in brain than in other tissues (GTEx data).

**PPI Network**

We analyzed 109 MT-nDNA proteins using the PPI network (see Web Resources)87,88 to identify 4,132 interacting proteins. We present the 15 top genes (Table S11) with highest PageRank score for PPI,89–91 including the number of PPI, a short description of gene's function from Gene Entrez of NCBI-db, associated trait(s), and association p value(s) (see also Supplemental Material and Methods, section 9). From the PPI analysis it is evident that a gene/protein hub (which is assumed important because of a relatively large number of interactions) is not necessary, the top-notch for association with a specific trait, as shown in the Discussion section.
Discussion

This large, comprehensive study of human mitochondrial and nuclear mitochondrial genetic variation in relation to seven key risk factors for metabolic disease provides important information toward a better understanding of the causes and mechanisms of these phenotypes. The use of a two-tiered approach—i.e., examining mtDNA variants for up to \( \sim 170,202 \) individuals and nuclear MT-nDNA candidate gene polymorphisms for up to \( \sim 339,000 \) individuals—facilitated the evaluation of the genetic underpinnings of seven metabolic traits reflecting adiposity/obesity and glucose-insulin metabolism and signaling. We identified two mtDNA SNVs (in \( MT\text{-}ATP6 \) and the D-loop) associated with WHR and fasting glucose, a burden of SNVs in a gene (\( MT\text{-}ND3 \)) associated with BMI, and five rare SNVs of mtDNA (in \( MT\text{-}ATP6 \), \( MT\text{-}ND5 \), and \( MT\text{-}ND6 \)) associated with BMI (2 of 3), with WHR (2 of 3), and with fasting insulin (1 of 3). Additionally, the MT-nDNA meta-analysis implicated significant associations with 62 of 109 protein coding candidate genes (\( p \leq 5 \times 10^{-8} \)), 29 additional passing the above threshold for the metabolic traits considered herein or any other traits querying the GWAS catalog (see Web Resources). Only 16% of MT-nDNA findings passed \( p \leq 1 \times 10^{-6} \) but did not reach \( p \leq 5 \times 10^{-8} \), and thus may be considered as new MT-nDNA contributions in association with seven metabolic traits (Tables 4 and S12). Enrichment analysis showed that 13 of MT-nDNA genes have also been identified as candidate genes for T2D risk and 18 for CVD risk. The eQTL analysis of MT-nDNA candidates revealed that approximately 27% of associations with seven metabolic traits also act as eSNVs in regulating expression of other cis-genes. In addition, \( \text{trans-eQTL} \) analysis yielded potential support for maternal energy generation have been identified. These rare mitochondrial genetic diseases commonly result in multiple clinical phenotypes with varying penetrance, likely due to differences in heteroplasmy. In our study, \( MT\text{-}ATP6 \) variants MT-8706 and MT-8896 (rs202120082), one with MAF > 1% and the other one rare, respectively, were both associated with WHR. \( MT\text{-}ATP6 \) is part of the proton-transporting portion of ATP synthase, contributing to its rotational mechanism. \( MT\text{-}16320 \) (rs62581338; MAF > 1%), in the D-loop, which contains a few mtDNA replication origins and is possibly involved in accelerating mtDNA synthesis to satisfy developmental, physiological, or aging-related demands, displayed a significant association with glucose. MT-16320 is less than 1 kb from a major mtDNA transcription initiation site (IT) that overlaps with promoters (in the D-loop in H-strand, IT\(_{H1}\) at 561 bps and IT\(_{H2}\) at 630, and in L-strand at 407 bps (IT\(_{L1}\)) and is 500 bps downstream of mitochondrial-encoded cytochrome b (\( MT\text{-}CYB \) [MIM: 516020], plus strand) and 2 kb upstream of \( MT\text{-}ND6 \) (minus strand).

Of the five rare SNVs, MT-14272 (rs2853814, missense), MT-14353, and MT-14584 of \( MT\text{-}ND6 \) were associated with adiposity-related traits. \( MT\text{-}ND6 \) is a core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (complex I) and is part of the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH into the respiratory chain, while
coupling the flow of electrons to the pumping of protons. We also demonstrated an association between insulin and rare variant MT-14124 in the closely related MT-ND5 gene. MT-ND5 is also a core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (complex I).

Future studies need to validate these rare variant mtDNA findings.

It is also important to note that we observed several rare gene-based suggestive associations between our metabolic traits (p ≤ 5E-02, Tables 2 and 3) and non-protein coding genes, primarily tRNAs. Mutations within tRNAs that impact translation would impact all of the mtDNA-encoded peptides and consequently would be expected to have significant effects on oxidative phosphorylation. The MT-ND3 gene displayed an aggregate of low-frequency variants associated with BMI. MT-ND3 is a subunit of the respiratory chain complex I that is part of the minimal assembly of core proteins required to catalyze NADH dehydrogenation and electron transfer to ubiquinone (co-enzyme Q10). Interestingly, previous studies have demonstrated increased MT-ND3 gene expression associated with a higher histological severity of hepatic steatosis. Gene-based meta-analysis burden test, which employed inverse variance weighting to combine association results from 82 variants in MT-ND3 gene across cohorts, yielded a significant association between MT-ND3 and BMI (p = 1E–03, Figure S17). This figure illustrates that rare alleles of 82 SNVs contributing in the MT-ND3 meta-analysis have variable effects.

We used GTEx data for mtDNA genes as assembled by the Human Protein Atlas team (see Web Resources). They showed the highest expression of RNA for the MT-ATP6, MT-ND3, MT-ND5, and MT-ND6 significant mtDNA genes in the heart and brain, which represent the highest energy-demanding tissues as compared, for example, to adipose tissue, in a ratio of about 3:1 (Figure S13). The importance of MT-nDNA and mtDNA gene polymorphisms in the heart is supported by recent publications that have summarized the relation of MT to vascular function, as therapeutic targets in heart failure, and specific genes and pathways that relate to the heart.
G6PD protein has a weak score of 1 out of 5 to be found in MT. G6PD is mainly localized in the cytosol and also to the microtubule-organizing center and vesicles (Human Protein Atlas). G6PD protein has 69 interactions and was ranked 65th by the PageRank algorithm for the importance of PPI. These results taken together may suggest that G6PD contributes to the maternal epigenetics of T2D, through X chromosome inheritance and less through MT. Other candidates of MT-nDNA genes that may contribute to mitochondrial epigenetics are DNMT1 (19p13.2 [MIM: 126375], DNA methyltransferase 1), POLRMT (19p13.3 [MIM: 601778], RNA polymerase mitochondrial), TFB1M (6q25.3 [MIM: 607033], transcription factor B1, mitochondrial), TFB2M (1q44 [MIM: 607055], transcription factor B2, mitochondrial), and TEAM (10q21.1 [MIM: 600438], transcription factor A, mitochondrial), but showed no significant associations with existing data for the traits studied (for BMI: rs6926853, TFB1M, p = 1.3E–03; WHR: rs10465617, TFB2M, p = 3.1E–03; glucose: rs4804124, DNMT1, p = 7.3E–05; insulin: rs7253062, DNMT1, p = 4.4E–03; HOMA-B: rs12462004, DNMT1, p = 4.4E–03; HOMA-IR: rs892189, DNMT1, p = 7E–04; HbA1c: rs11006132, TFAM, p = 2.4E–03).121

MT-nDNA Candidate Genes Associations (Adipose Traits)

We found that a total of 26 of the 109 MT-nDNA candidate genes showed significant associations with WHR (Tables 4 and S6 and Figure S11). For example, WARS2 (1p12 [MIM: 604733]) encodes the mitochondrial tryptophanyl-tRNA synthetase. We observed an intronic rs6428792 of WARS2 in association with WHR (p = 7.95E–18).50 Another SNV, rs10923724 in LD with rs6428792, r^2 = 0.29, WHR p = 9E–25) upstream of WARS2 but closer to downstream of TBX15 (1p12 [MIM: 604127]), modifies WARS2 expression in skeletal muscle (p = 1.1E–36) and in adipose-subcutaneous tissues (p = 1E–29) (GTeX data). In our PPI analysis of 109 MT-nDNA genes and 4,132 interactants, WARS2 showed two interactions and was ranked 2,028th based on the PageRank algorithm. Taken together, these findings (our study, GTeX, and GWAS) suggest that associations with WHR might be mediated also by differential expression of WARS2.122

There were 48 MT-nDNA candidates associating with BMI. For example, NPC1 (18p11.2, Tables 4 and S6) has been associated with early childhood onset and adult morbid obesity.122 NPC1 (a cholesterol transporter) is highly expressed in human white adipose tissue adipocytes with increased levels in obese individuals.123 Our lead SNV rs1788785 is an eSNV for NPC1 and is not in LD with the best NPC1 eSNV, supporting NPC1 as a candidate gene for obesity. Indeed, studies in mice have shown that a non-functioning NPC1 resulted in late-onset weight loss and less food intake.124 In humans, NPC1 is part of the cholesterol metabolism pathway (see Web Resources). Recently, NPC1 mutant cells were reported to have fragmented mitochondrial networks, increased respiration, alterations in the composition of the respiratory chain complex, and a substantial reduction in the cellular ATP level. Thus, a primary lysosomal defect in NPC1 mutant fibroblasts is accompanied by deregulation of the organization and function of the mitochondrial network.125 NPC1 was ranked 241st and had 13 interactions in the PPI network.

Other notable obesity-related variants/genes among MT-nDNA candidates include POMC (2p23.3, adrenocorticotropic peptide/hormone, p = 7.2E–07), which binds to melanocortin 2 receptor (MC2R, 18p11.21 [MIM: 607397]), stimulating release of cortisol, a steroid stress-response hormone. MC4R (18q21.32, p = 6.4E–14) was ranked the 3rd in BMI-effects compared to FTO (16q12.2 [MIM: 610966]), the top ranked for BMI effects in Speliotes et al.,41 Locke et al.,46 and Winkler et al.48 MC4R is another member of the melanocortin receptor family, which has a central role in energy homeostasis and somatic growth. MC4R is ranked the 82nd, with 12 PPI, when analyzed for the importance of PPI using the PageRank algorithm. CNR1 (6q15 [MIM: 114610], cannabinoid receptor, p = 9.6E–07) influences mitochondrial respiration. CRTC1 (19p13.11 [MIM: 607536], CREB regulated transcription coactivator 1, p = 8.8E–09) is a potent coactivator of PGC1a (4p15.2, officially known as PPARGC1A [MIM: 604517]), a transcriptional coactivator that regulates the genes involved in energy metabolism, and inducer of mitochondrial biogenesis.

**MTCH2** (11p11.2, mitochondrial carrier homolog 2, rs7118178, BMI p = 5.1E–08) was 9th in BMI effects compared to FTO in Speliotes et al.41 and 16th in Locke et al.46 MTCH2 is located in the inner membrane of MT, highly expressed in white adipose tissue and adipocytes, and is thought to play a regulatory role in adipocyte differentiation and biology.126 The MTCH2 GWAS-variant rs7118178 (Table 4) has been associated with BMI, glucose,36,55 and pro-insulin 58 (Figure 4, T1-4). MTCH2 has 87 protein interactions and ranked 14th when analyzed for the importance of PPI using PageRank algorithm. MTCH2 deficiency in mouse muscle has been shown to be beneficial, protecting mice from the obesogenic effect of high-fat diets, most likely the result of an increase in mitochondrial metabolism. MTCH2 is proposed as a repressor of muscle mitochondrial metabolism and size.127 Using both GWAS and eQTL information, three MTCH2 SNVs co-localize within a 15 kbp DNA region. Based on GTEx data, rs4752856 in MTCH2 (Figure 4, T6) regulates gene expression of C1QTNF4 (11p11.2 [MIM: 614911]) and PSMC3 (11p11.2 [MIM: 186852]) in subcutaneous adipose tissue. rs3817335, which is in high LD (r^2 = 0.903) with rs4752856, regulates SLC39A13 (11p11.2 [MIM: 608735]) in tibial artery tissue, while rs7118178 (in less LD to two other SNVs, r^2 = 0.083) regulates CELF1 (11p11.2 [MIM: 601074]) in tibial nerve tissue, and with results similar to the best eSNVs for the mentioned genes and in high LD with their eSNVs (Figure 4, T5). C1QTNF4 is reported as a potential cytokine
that can induce the activation of both NFKB1 (MIM: 164011) and IL6/STAT3 (MIM: 147620/102582) signaling pathways and acts in the hypothalamus to modulate food intake and peripheral energy expenditure. 129 PSMC3 is involved in ATP-dependent degradation of misfolded and damaged proteins and in removal of no longer required proteins. This protein is also involved in cell cycle progression, apoptosis, and DNA damage repair. A knock-down of PSMC3 in human immortalized fibroblasts increased cell proliferation. 130 CELF1 has been associated with Alzheimer disease and obesity. 131 Consequently, MTCH2 effects on BMI may be more complex than previously accounted for. Other Functions of MT-nDNA Candidate Genes

Mitochondrial inheritance has been previously associated with obesity, metabolic syndrome, insulin resistance, type 2 diabetes, and cardiovascular disease. 3,40,132–135 The complex genetics of MT affects processes of glucose, lipid, and amino acid catabolism, with ATP as the final energy product. By-products of these processes play an important role in signaling (e.g., ROS) and are used for epigenetic modifications (e.g., acetyl CoA). In our study, we would expect a preponderance of glycemic and lipid genes and proteins. Out of 109 MT-nDNA candidate genes, 21 of the significantly associated genes were functionally related with cholesterol (Table S6 and Figure S11), 16 with glucose and insulin, and 5 with adipose/obesity. The 109 MT-nDNA candidate genes have other functions too. For example, rs1044661 is located at 17q25.3, overlapping two genes that run in opposite strands: TBCD (involved in tubulin folding as cofactor D) and B3GNTL1 (a putative glucosyltransferase). This SNV was associated with HbA1c (p = 1.74E−46).61 Recently, Francis et al. 136 hypothesized that the interaction between TBCD (17q25.3) and ARL2 (11q13.1 [MIM: 601175]) suggest that ARL2 serves as regulator of both mitochondrial fusion and microtubule dynamics. In 109 MT-nDNA candidates, WDR78 (1p31.3), TRIM54 (2p23.3 [MIM: 606474], regulating titin kinase [controlling elasticity in muscle] and microtubule-dependent signaling pathways in striated muscles), DNM3 (1q24.3 [MIM: 611445], involved in vesicular transport and with biased expression in brain), MAP2 (2q34 [MIM: 157130], involved in microtubule assembly and neurogenesis), GJA1 (6q22.31 [MIM: 121014], involved in the...
contraction of heart) and MAPT (17q21.31, expressed in nervous system) produce microtubule-associated proteins in interaction with MT (Table S6 and Figure S11). It should be noted that rs1050828, a missense mutation of G6PD residing on X chromosome, may impact HbA1c through non-glycemic factors rather than glucose metabolism.\textsuperscript{61} Additional functions of MT-nDNA candidate genes are described in the Supplemental Material and Methods, section 7.

**Strengths and Limitations**

Our study had many strengths. We used large sample sizes for studying mtDNA and MT-nDNA. At the mtDNA level we validated SNVs used per cohort and imputed based on Cosmopolitan MT-1000 Genomes. At the MT-nDNA level we used the strength of many consortia contributions for associations with seven traits. As a consequence, we performed comprehensive mtDNA and MT-nDNA analyses. The seven mtDNA variants significant associations showed no statistical significant deviations from the homogeneity/similarity of beta contributions before meta-pooling across studies as reported with Het-p in Table 1, as well as graphically represented in the Forest plot (Figure S16). For supporting MT-future studies, we have provided mtDNA updated Tables S15–S28 for arrays used in this study including MitoMap annotation. Also, we include Table S32 of predictions from the bioinformatics platforms that have been shown to have the highest sensitivity and specificity for the mtDNA variants.\textsuperscript{137} Our study also had some limitations. Rare mtDNA mutations are usually heteroplasmic point mutations and/or mtDNA lesions that typically result in a primary mitochondrial disease, which can manifest as a broad range of clinical outcomes. In this study we have interrogated the effect of inherited mtDNA variants, much commoner in the population than typical mtDNA mutations. Therefore, while there is a great deal of literature linking inherited mtDNA variants to disease, many of these studies have limited statistical power\textsuperscript{138} and several have never been independently replicated. So in many respects there is not a great deal of robust literature to call upon. The harmonization of mtDNA in each study that the MT-candidates (SNVs/genes) have special significance for the mtDNA variants. A.T.K., C. Liu, J.L.F., M. Graff, C.T.H., C.G., L.R.Y., M.F.F., D.E.A., D.I.C., K.Y., W.D.H., S.J.L., L.W., T.J.B., L.D.L.-G., T.I.A.S., G. Hudson, D.L., A.N.M., D.M.B., M.A.P., L.R.Y., M.F.F., D.E.A., D.I.C., K.Y., W.D.H., S.J.L., L.W., T.J.B., L.D.L.-G., T.I.A.S., G. Hudson, D.L., A.N.M., D.M.B., M.A.P., J.B.M., J.I.R., and K.E.N. were the writing group for this paper. M.A.P. and K.E.N. are from the CHARGE ADIPOSITY working group; J.I.R. and J.B.M. are from the CHARGE DIABETES working group.

**Perspective and Conclusion**

We focused on associations of MT with adipose and glycemic traits, yet we acknowledge that there is still much to be learned from other traits, for example for triglycerides, high-density lipoprotein cholesterol, and C-reactive protein.\textsuperscript{46,139–141} Notably, we identified 21 MT genes of lipid metabolism, although this was not the direct focus of our study. For example, TMLHE (Xq28 [MIM: 300777], trimethyllysine dioxygenase associated with HbA1c, \( p = 2.2E-19 \)) is the first enzyme in the carnitine biosynthesis pathway. Carnitine play an essential role in the transport of activated fatty acids across the inner mitochondrial membrane and this gene is ubiquitous for its expression in heart. Hence, MT associations with other traits at the consortia-level remain to be explored. In conclusion, we identified common, rare SNVs, and a gene burden of genetic mtDNA variants, as well as 109 MT-nDNA genes associated with metabolic traits. Of the 109 MT-nDNA candidate genes, a subset pointed to associations with adipose, glucose metabolism, T2D, and CVD, and a subset of SNVs was inferred to contribute for differential regulatory genes expression. We documented in this study that the MT-candidates (SNVs/genes) have special contributions for functioning and energy homeostasis in adipose tissues and to glucose metabolism and insulin signaling.

**Accession Numbers**

Summary statistics for the mtDNA meta-analyses are available in the dbGaP\textsuperscript{v8.p1.}

**Supplemental Data**

Supplemental Data include 17 figures, 32 tables, Supplemental Material and Methods, Supplemental Acknowledgments, and Supplemental Study Descriptions and can be found with this article online at https://doi.org/10.1016/j.ajhg.2018.12.001.

**Acknowledgments**

A.E. Justice is supported by a K99/R00 from the National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI) (5K99HL130580-02 and 5R00HL130580-04). G. Hudson has received funding support by Wellcome Trust Centre for Mitochondrial Research, Grant Code G906919. J.I.R., X.G., Y.-D.I.C., K.D.T., Y.H., K.S., and J.Y. have received NIH support for research related to mitochondria. A.T.K., C. Liu, J.L.F., M. Graff, C.T.H., C.G., L.R.Y., M.F.F., D.E.A., D.I.C., K.Y., W.D.H., S.J.L., L.W., T.J.B., L.D.L.-G., T.I.A.S., G. Hudson, D.L., A.N.M., D.M.B., M.A.P., J.B.M., J.I.R., and K.E.N. were the writing group for this paper. M.A.P. and K.E.N. are from the CHARGE ADIPOSITY working group; J.I.R. and J.B.M. are from the CHARGE DIABETES working group.

**Declaration of Interests**

A.Y.C. is currently an employee of Merck & Co. C.T.-P. has received grants from Bayer pertaining to antithrombotic treatment of atrial fibrillation and cardiac valve replacements. D.O.M.-K. works as a part-time clinical research consultant for Metabolon, Inc. The remaining authors declare no competing financial interests.
Web Resources

1000 Genomes data (released April 2016), http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/
dbGap, https://www.ncbi.nlm.nih.gov/gap
EasyQC, http://www.genepi-regensburg.de/easyqc/
FCGENE, https://sourceforge.net/projects/fcgene/
GenBank (NCBI Reference Sequence: NC_012920.1), https://www.ncbi.nlm.nih.gov/nuccore/251831106
GIA NT Consortium repositories, https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files
GTEx (Gene Expression Portal), https://gtexportal.org
GWAS Catalog, http://www.ebi.ac.uk/gwas/
Human Mitochondrion Sequence, https://www.mitomap.org/
IMPUTE2, http://mathgen.stats.ox.ac.uk/impute/impute_v2.html
KEGG, https://www.genome.jp/dbget-bin/www_bget?hsa04979
MITOMAP/HumanMitoSeq
MAGIC consortium archives, https://www.magicinvestigators.org/downloads/
OMIM, http://www.omim.org/
Protein-Protein Interactions, ftp://ftp.ncbi.nih.gov/gene/GenefRIF/seqMeta
seqMeta release notes, https://cran.r-project.org/web/packages/seqMeta/seqMeta.pdf
SHAPEIT2, https://mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html#home
The Human Protein Atlas, http://www.proteinatlas.org/

References

1. Wang, Z., Ying, Z., Bosy-Westphal, A., Zhang, J., Schautz, B., Later, W., Heymsfield, S.B., and Müller, M.J. (2010). Specific metabolic rates of major organs and tissues across adulthood: evaluation by mechanistic model of resting energy expenditure. Am. J. Clin. Nutr. 92, 1369–1377.
2. Ernster, L., and Schatz, G. (1981). Mitochondria: a historical review. J. Cell Biol. 91, 227s–255s.
3. Chow, J., Rahman, J., Achermann, J.C., Dattani, M.T., and Dattani, M.T., and Rahman, S. (2017). Mitochondrial disease and endocrine dysfunction. Nat. Rev. Endocrinol. 13, 92–104.
4. Prasad, K. (2017). Regulation of mitochondrial structure and function by protein import: A current review. Pathophysiology 24, 107–122.
5. Lang, B.F., Gray, M.W., and Burger, G. (1999). Mitochondrial genome evolution and the origin of eukaryotes. Annu. Rev. Genet. 33, 351–397.
6. Pagliarini, D.J., Calvo, S.E., Chang, B., Sheth, S.A., Vafai, S.B., Ono, S.E., Walford, G.A., Sugiana, C., Boneh, A., Chen, W.K., et al. (2008). A mitochondrial protein compendium elucidates complex I disease biology. Cell 134, 112–123.
7. Smith, A.C., and Robinson, A.J. (2016). MitoMiner v3.1, an update on the mitochondrial proteomics database. Nucleic Acids Res. 44 (D1), D1258–D1261.
8. Febbo, P.G., Mulligan, M.G., Slonina, D.A., Stegmaier, K., Di Vizio, D., Martinez, P.R., Loda, M., and Taylor, S.C. (2007). Literature Lab: a method of automated literature integration to infer biology from microarray analysis. BMC Genomics 8, 461.
9. Haag-Liautard, C., Coffey, N., Houle, D., Lynch, M., Charlesworth, B., and Knightley, P.D. (2008). Direct estimation of the mitochondrial DNA mutation rate in Drosophila melanogaster. PLoS Biol. 6, e204.
10. Neiman, M., and Taylor, D.R. (2009). The causes of mutation accumulation in mitochondrial genomes. Proc. Biol. Sci. 276, 1201–1209.
11. Craven, L., Alston, C.L., Taylor, R.W., and Turnbull, D.M. (2017). Recent advances in mitochondrial disease. Annu. Rev. Genomics Hum. Genet. 18, 257–275.
12. Schaefer, A.M., Walker, M., Turnbull, D.M., and Taylor, R.W. (2013). Endocrine disorders in mitochondrial disease. Mol. Cell. Endocrinol. 379, 2–11.
13. Malik, A.N., and Czajka, A. (2013). Is mitochondrial DNA content a potential biomarker of mitochondrial dysfunction? Mitochondrion 13, 481–492.
14. Ashar, F.N., Moes, A., Moore, A.Z., Grove, M.L., Chaves, P.H.M., Coresh, J., Newman, A.B., Matteini, A.M., Bandeen-Roche, K., Boerwinkle, E., et al. (2015). Association of mitochondrial DNA levels with frailty and all-cause mortality. J. Mol. Med. (Berl.) 93, 177–186.
15. Mengel-From, J., Thinggaard, M., Dalgård, C., Kyvik, K.O., Christensen, K., and Christiansen, L. (2014). Mitochondrial DNA copy number in peripheral blood cells declines with age and is associated with general health among elderly. Hum. Genet. 133, 1149–1159.
16. Ashar, F.N., Zhang, Y., Longchamps, R.J., Lane, J., Moes, A., Grove, M.L., Mychaleckyj, J.C., Taylor, K.D., Coresh, J., Rotter, J.L., et al. (2017). Association of mitochondrial DNA copy number with cardiovascular disease. JAMA Cardiol. 2, 1247–1255.
17. Zhang, Y., Guallar, E., Ashar, F.N., Longchamps, R.J., Castellani, C.A., Lane, J., Grove, M.L., Coresh, J., Sotoodehnia, N., Ilkhanoff, L., et al. (2017). Association between mitochondrial DNA copy number and sudden cardiac death: findings from the Atherosclerosis Risk in Communities study (ARIC). Eur. Heart J. 38, 3443–3448.
18. Tin, A., Grams, M.E., Ashar, F.N., Lane, J.A., Rosenberg, A.Z., Grove, M.L., Boerwinkle, E., Selvin, E., Coresh, J., Pankratz, N., and Arking, D.E. (2016). Association between mitochondrial DNA copy number in peripheral blood and incident CKD in the Atherosclerosis Risk in Communities Study. J. Am. Soc. Nephrol. 27, 2467–2473.
19. Heinonen, S., Buzkova, J., Muniandy, M., Kaksonen, R., Olikainen, M., Ismail, K., Hakkarainen, A., Lundbom, J., Lundbom, N., Vuolteenaho, K., et al. (2015). Impaired mitochondrial biogenesis in adipose tissue in acquired obesity. Diabetes 64, 3135–3145.
20. De Pauw, A., Tejerina, S., Raes, M., Keijer, J., and Arnould, T. (2009). Mitochondrial (dys)function in adipocyte (de)differentiation and systemic metabolic alterations. Am. J. Pathol. 175, 927–939.
21. Altschuler-Keylin, S., and Kajimura, S. (2017). Mitochondrial homeostasis in adipose tissue remodeling. Sci. Signal. 10, 10.
22. Montgomery, M.K., and Turner, N. (2015). Mitochondrial dysfunction and insulin resistance: an update. Endocr. Connect. 4, R1–R15.
23. Vernochet, C., Damiiano, F., Mourier, A., Bezy, O., Mori, M.A., Smyth, G., Rosenzweig, A., Larsson, N.G., and Kahn,
24. Wiklund, P., Zhang, X., Pekkala, S., Autio, R., Kong, L., Yang, Y., Keinänen-Kiukaanniemi, S., Aten, M., and Cheng, S. (2016). Insulin resistance is associated with altered amino acid metabolism and adipose tissue dysfunction in normoglycemic women. Sci. Rep. 6, 24540.

25. Beasley, T.M., Erickson, S., and Allison, D.B. (2009). Rank-based inverse normal transformations are increasingly used, but are they merited? Behav. Genet. 39, 580–595.

26. Kearse, M., Moir, R., Wilson, A., Stones-Havas, S., Cheung, M., Sturrock, S., Buxton, S., Cooper, A., Markowitz, S., Duran, C., et al. (2012). Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics 28, 1647–1649.

27. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly, M.J., and Sham, P.C. (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575.

28. Chang, C.C., Chow, C.C., Tellier, L.C., Vattikuti, S., Purcell, S.M., and Lee, J.J. (2015). Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4, 7.

29. Delaneau, O., Zagury, J.F., and Marchini, J. (2013). Improved whole-chromosome phasing for disease and population genetic studies. Nat. Methods 10, 5–6.

30. Howie, B.N., Donnelly, P., and Marchini, J. (2009). A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 5, e1000529.

31. Delaneau, O., Marchini, J.; and 1000 Genomes Project Consortium (2014). Integrating sequence and array data to create an improved 1000 Genomes Project haplotype reference panel. Nat. Commun. 5, 3934.

32. Winkler, T.W., Day, F.R., Croteau-Chonka, D.C., Wood, A.R., Locke, A.E., Mägi, R., Ferreira, T., Fall, T., Graff, M., Justice, A.E., et al.; Genetic Investigation of Anthropometric Traits (GIANT) Consortium (2014). Quality control and conduct of genome-wide association meta-analyses. Nat. Protoc. 9, 1192–1212.

33. Chen, H., Meigs, J.B., and Dupuis, J. (2013). Sequence kernel association test for quantitative traits in family samples. Genet. Epidemiol. 37, 196–204.

34. Liu, C., Dupuis, J., Larson, M.G., and Levy, D. (2013). Association testing of the mitochondrial genome using pedigree data. Genet. Epidemiol. 37, 239–247.

35. Willer, C.J., Li, Y., and Abecasis, G.R. (2010). METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190–2191.

36. Huang, H., Chanda, P., Alonso, A., Bader, J.S., and Arking, D.E. (2011). Gene-based tests of association. PLoS Genet. 7, e1002177.

37. Wang, L., Lee, S., Gim, J., Qiao, D., Cho, M., Elston, R.C., Silverman, E.K., and Won, S. (2016). Family-based rare variant association analysis: A fast and efficient method of multivariate phenotype association analysis. Genet. Epidemiol. 40, 502–511.

38. Lee, S., Abecasis, G.R., Boehnke, M., and Lin, X. (2014). Rare-variant association analysis: study designs and statistical tests. Am. J. Hum. Genet. 95, 5–23.

39. Calvo, S.E., Clauser, K.R., and Mootha, V.K. (2016). Mitocarta2.0: an updated inventory of mammalian mitochondrial proteins. Nucleic Acids Res. 44 (D1), D1251–D1257.

40. Lu, H., Koshkin, V., Allister, E.M., Gyulikhandyan, A.V., and Wheeler, M.B. (2010). Molecular and metabolic evidence for mitochondrial defects associated with beta-cell dysfunction in a mouse model of type 2 diabetes. Diabetes 59, 448–459.

41. Speliotes, E.K., Willer, C.J., Berndt, S.I., Monda, K.L., Thorleifsson, G., Jackson, A.U., Lango Allen, H., Lindgren, C.M., Lu, J., Mägi, R., et al.; MAGIC; and Procardis Consortium (2010). Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat. Genet. 42, 937–948.

42. Yang, J., Loos, R.J., Powell, J.E., Medland, S.E., Speliotes, E.K., Chapman, D.I., Rose, L.M., Thorleifsson, G., Steinhorsdottir, V., Mägi, R., et al. (2012). FTO genotype is associated with phenotypic variability of body mass index. Nature 490, 267–272.

43. Berndt, S.I., Gustafsson, S., Mägi, R., Ganna, A., Wheeler, E., Feitosa, M.F., Justice, A.E., Monda, K.L., Croteau-Chonka, D.C., Day, F.R., et al. (2013). Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat. Genet. 45, 501–512.

44. Randall, J.C., Winkler, T.W., Kutalik, Z., Berndt, S.I., Jackson, A.U., Monda, K.L., Kilpeläinen, T.O., Esko, T., Mägi, R., Li, S., et al.; DIAGRAM Consortium; and MAGIC Investigators (2013). Sex-stratified genome-wide association studies including 270,000 individuals show sexual dimorphism in genetic loci for anthropometric traits. PLoS Genet. 9, e1003500.

45. Monda, K.L., Chen, G.K., Taylor, C.K., Palmer, C., Edwards, T.L., Lange, L.A., Ng, M.C., Adeyemo, A.A., Allison, M.A., Bialik, L.F., et al.; NABEC Consortium; UKBEC Consortium; BioBank Japan Project; and AGEN Consortium (2013). A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat. Genet. 45, 690–696.

46. Locke, A.E., Kahali, B., Berndt, S.I., Justice, A.E., Pers, T.H., Day, F.R., Powell, C., Vedantam, S., Buchkovich, M.L., Yang, Y., et al.; LifeLines Cohort Study; ADIPOGen Consortium; AGEn-BMI Working Group; CARDIOGRAMplusC4D Consortium; CKDGen Consortium; GLGC; ICBP; MAGIC Investigators; MuTHER Consortium; MIGen Consortium; PAGE Consortium; ReproGen Consortium; GENIE Consortium; and International Endogene Consortium (2015). Genetic studies of body mass index yield new insights for obesity biology. Nature 518, 197–206.

47. Shungin, D., Winkler, T.W., Croteau-Chonka, D.C., Ferreira, T., Locke, A.E., Mägi, R., Strawbridge, R.J., Pers, T.H., Fischer, K., Justice, A.E., et al.; ADIPOGen Consortium; CARDIOGRAMplusC4D Consortium; CKDGen Consortium; GLGC; ICBP; MAGIC Investigators; MuTHER Consortium; MIGen Consortium; PAGE Consortium; ReproGen Consortium; and International Endogene Consortium (2015). New genetic loci link adipose and insulin biology to body fat distribution. Nature 518, 187–196.

48. Winkler, T.W., Justice, A.E., Graff, M., Barata, L., Feitosa, M.F., Chu, S., Czajkowskij, J., Kosk, T., Fall, T., Kilpeläinen, T.O., et al.; CHARGE Consortium; DIAGRAM Consortium; GLGC Consortium; Global-BPGen Consortium; ICBP Consortium; and MAGIC Consortium (2015). The influence of age and sex on genetic associations with adult body size...
and shape: a large-scale genome-wide interaction study. PLoS Genet. 11, e1005378.

49. Ng, M.C.Y., Graff, M., Lu, Y., Justice, A.E., Mudgal, P., Liu, C.T., Young, K., Yanek, L.R., Feitosa, M.F., Wojciszynski, M.K., et al.; Bone Mineral Density in Childhood Study (BMDCS) Group (2017). Discovery and fine-mapping of adiposity loci using high density imputation of genome-wide association studies in individuals of African ancestry: African Ancestry Anthropometry Genetics Consortium. PLoS Genet. 13, e1006719.

50. Justice, A.E., Winkler, T.W., Feitosa, M.F., Graff, M., Fisher, V.A., Young, K., Barata, L., Deng, X., Czajkowski, J., Hadley, D., et al. (2017). Genome-wide meta-analysis of 241,258 adults accounting for smoking behaviour identifies novel loci for obesity traits. Nat. Commun. 8, 14977.

51. Heid, I.M., Jackson, A.U., Randall, J.C., Winkler, T.W., Qi, L., Steinthorsdottir, V., Thorleifsson, G., Zillikens, M.C., Spielotes, E.K., Magi, R., et al.; MAGIC (2010). Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat. Genet. 42, 949–960.

52. Graff, M., Scott, R.A., Justice, A.E., Young, K.L., Feitosa, M.F., Barata, L., Winkler, T.W., Chu, A.Y., Mahajan, A., Hadley, D., et al.; CHARGE Consortium; EPIC-InterAct Consortium; and PAGE Consortium (2017). Genome-wide physical activity interactions in adiposity - A meta-analysis of 200,452 adults. PLoS Genet. 13, e1006528.

53. Saxena, R., Hivert, M.F., Langenberg, C., Tanaka, T., Pankow, J.S., Vollenweider, P., Lyssenko, V., Bouatia-Naji, N., Dupuis, J., Jackson, A.U., et al.; GIANT consortium; and MAGIC investigators (2010). Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat. Genet. 42, 142–148.

54. Dupuis, J., Langenberg, C., Prokopenko, I., Saxena, R., Soranzo, N., Jackson, A.U., Wheeler, E., Glazer, N.L., Bouatia-Naji, N., Gloyn, A.L., et al.; DIAGRAM Consortium; GIANT Consortium; Global BPgen Consortium; Anders Hamsten on behalf of Procardis Consortium; and MAGIC investigators (2010). New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat. Genet. 42, 105–116.

55. Manning, A.K., Hivert, M.F., Scott, R.A., Grimsby, J.L., Bouatia-Naji, N., Chen, H., Rybin, D., Liu, C.T., Bielak, L.F., Prokopenko, I., et al.; DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium; and Multiple Tissue Human Expression Resource (MUTHER) Consortium (2012). A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemric traits and insulin resistance. Nat. Genet. 44, 659–669.

56. Scott, R.A., Lagou, V., Welch, R.P., Wheeler, E., Montasser, M.E., Luan, J., Magi, R., Strawbridge, R.J., Rehnberg, E., Gustafsson, S., et al.; DIAbetes Genetics Replication and Meta-analysis (DIAGRAM) Consortium (2012). Large-scale association analyses identify new loci influencing glycemric traits and provide insight into the underlying biological pathways. Nat. Genet. 44, 991–1005.

57. Prokopenko, I., Poon, W., Magi, R., Prasad B, R., Salehi, S.A., Almgren, P., Osmark, P., Bouatia-Naji, N., Wierup, N., Fall, T., et al. (2014). A central role for GRB10 in regulation of islet function in man. PLoS Genet. 10, e1004235.

58. Strawbridge, R.J., Dupuis, J., Prokopenko, I., Barker, A., Ahlqvist, E., Rybin, D., Petrie, J.R., Travers, M.E., Bouatia-Naji, N., Dimas, A.S., et al.; DIAGRAM Consortium; GIANT Consortium; MuTHER Consortium; CARDioGRAM Consortium; and 4D Consortium (2011). Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes 60, 2624–2634.

59. Walford, G.A., Gustafsson, S., Rybin, D., Stancakova, A., Chen, H., Liu, C.T., Hong, J., Jensen, R.A., Rice, K., Morris, A.P., et al. (2016). Genome-wide association study of the modified Stumvoll insulin sensitivity index identifies BCL2 and FAM19A2 as novel insulin sensitivity loci. Diabetes 65, 3200–3211.

60. Soranzo, N., Sanna, S., Wheeler, E., Gieger, C., Radke, D., Dupuis, J., Bouatia-Naji, N., Langenberg, C., Prokopenko, I., Stolerman, E., et al.; WTCCC (2010). Common variants at 10 genomic loci influence hemoglobin A1C levels via glycemic and nonglycemic pathways. Diabetes 59, 3229–3239.

61. Wheeler, E., Leong, A., Liu, C.T., Hivert, M.F., Strawbridge, R.J., Podmore, C., Li, M., Yao, J., Sim, X., Hong, J., et al.; EPIC-CVD Consortium; EPIC-InterAct Consortium; and Michigan Biobank (2017). Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease. Nat. Genet. 49, 1450–1457.

62. Spracklen, C.N., Chen, P., Kim, Y.J., Wang, X., Cai, H., Li, S., Long, J., Wu, Y., Wang, Y.X., Takeuchi, E., et al. (2017). Association analyses of East Asian individuals and trans-ancestry analyses with European individuals reveal new loci associated with cholesterol and triglyceride levels. Hum. Mol. Genet. 26, 1770–1784.

63. Nelson, C.P., Goel, A., Butterworth, A.S., Howson, J.M.M., Assimes, T.L., Chowdhury, R., Homolander, M., Damrauer, S., et al.; CHD Exome+ Consortium; EPIC-CVD Consortium; EPIC-InterAct Consortium; and Michigan Biobank (2017). Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease. Nat. Genet. 49, 1385–1391.

64. Eppinga, R.N., Hagemeijer, Y., Burgess, S., Hinds, D.A., Stefansson, K., Gudbjartsson, D.F., van Veldhuisen, D.J., Munro, P.B., Verweij, N., and van der Harst, P. (2016). Identification of genomic loci associated with resting heart rate and shared genetic predictors with all-cause mortality. Nat. Genet. 48, 1557–1563.

65. Warren, H.R., Evangelou, E., Cabrera, C.P., Gao, H., Ren, M., Mifsud, B., Ntalla, I., Surendran, P., Liu, C., Cook, J.P., et al.; International Consortium of Blood Pressure (ICBP) 1000G Analyses; BIOS Consortium; Lifelines Cohort Study; Understanding Society Scientific group; CHD Exome+ Consortium; ExomeBP Consortium; T2D-GENES Consortium; GoT2DGenes Consortium; Cohorts for Heart and Ageing...
Research in Genome Epidemiology (CHARGE) BP Exome Consortium; International Genomics of Blood Pressure (iGEN-BP) Consortium; and UK Biobank CardioMetabolic Consortium BP working group (2017). Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. Nat. Genet. 49, 403–415.

68. Sabater-Lleal, M., Huang, J., Chasman, D., Naitza, S., Dehghan, A., Johnson, A.D., Teumer, A., Reiner, A.P., Folker, L., Basu, S., et al.; VTE Consortium; STROKE Consortium: Wellcome Trust Case Control Consortium 2 (WTCCC2); C4D Consortium; and CARDIoGRAM Consortium (2013). Multiethnic meta-analysis of genome-wide association studies in >100 000 subjects identifies 23 fibrinogen-associated loci but no strong evidence of a causal association between circulating fibrinogen and cardiovascular disease. Circulation 128, 1310–1324.

69. Willer, C.J., Schmidt, E.M., Sengupta, S., Peloso, G.M., Gustafsson, S., Kanoni, S., Ganna, A., Shen, J., Buchkovich, M.L., Mora, S., et al.; Global Lipids Genetics Consortium (2013). Discovery and refinement of loci associated with lipid levels. Nat. Genet. 45, 1274–1283.

70. Mozaffarian, D., Kabagambe, E.K., Johnson, C.O., Lemaitre, R.N., Manichaikul, A., Sun, Q., Foy, M., Wang, L., Wiener, H., Irvin, M.R., et al. (2015). Genetic loci associated with circulating phospholipid trans fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium. Am. J. Clin. Nutr. 101, 398–406.

71. Yeo, A., Li, L., Warren, L., Aponte, J., Fraser, D., King, K., Johannson, K., Barnes, A., MacPhee, C., Davies, R., et al. (2017). Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib. PLoS ONE 12, e0182115.

72. Hinds, D.A., Buil, A., Ziemek, D., Martinez-Perez, A., Malik, R., Folker, L., Germain, M., Malahrtig, A., Brown, A., Soria, J.M., et al.; METASTROKE Consortium, INVENT Consortium (2016). Genome-wide association analysis of self-reported events in 61,351 individuals and 252,827 controls identifies 8 loci associated with thrombosis. Hum. Mol. Genet. 25, 1867–1874.

73. Ehret, G.B., Munroe, P.B., Rice, K.M., Bochud, M., Johnson, A.D., Chasman, D.I., Smith, A.V., Tobin, M.D., Verwoert, G.C., Hwang, S.J., et al.; International Consortium for Blood Pressure Genome-Wide Association Studies; CARDIoGRAM consortium; C4D Gen consortium; KidneyGen Consortium; EchoGen Consortium; and CARDIoGRAM+CHARGE consortium (2011). Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 478, 103–109.

74. van der Harst, P., van Setten, J., Verweij, N., Vogler, G., Franke, L., Maurano, M.T., Wang, X., Mateo Leach, I., Eijgelshoven, M., Sotoodehnia, N., et al. (2016). 52 genetic loci influencing myocardial mass. J. Am. Coll. Cardiol. 68, 1435–1448.

75. Pott, J., Burkhardt, R., Beutner, F., Horn, K., Teren, A., Kirste, H., Holdt, L.M., Schuler, G., Teupser, D., Loeffler, M., et al. (2017). Genome-wide meta-analysis identifies novel loci of plaque burden in carotid artery. Atherosclerosis 259, 32–40.

76. Yasuno, K., Bilguvar, K., Bijlenga, P., Low, S.K., Krischek, B., Auburger, G., Simon, M., Krex, D., Arliet, Z., Nayak, N., et al. (2010). Genome-wide association study of intracranial aneurysm identifies three new risk loci. Nat. Genet. 42, 420–425.

77. Aulchenko, Y.S., Ripatti, S., Lindqvist, I., Boomsma, D., Heid, I.M., Pramstaller, P.P., Penninx, B.W., Janssens, A.C., Wilson, J.F., Spector, T., et al.; ENGAGE Consortium (2009). Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat. Genet. 41, 47–55.

78. Boyle, A.P., Hong, E.L., Hariharan, M., Cheng, Y., Schaub, M.A., Kasowskii, M., Karczewski, K.J., Park, J., Hitz, B.C., Weng, S., et al. (2012). Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 22, 1790–1797.

79. Esters, N., Rohrer, J.D., Hardy, J., Wray, S., and Abramov, A.Y. (2017). Mitochondrial hyperpolarization in iPSC-derived neurons from patients of FTDP-17 with 10+16 MAPT mutation leads to oxidative stress and neurodegeneration. Redox Biol. 12, 410–422.

80. Ward, L.D., and Kellis, M. (2012). HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 40, D930–D934.

81. Battle, A., Brown, C.D., Engelhardt, B.E., Montgomery, S.B.; GTEx Consortium; Laboratory, Data Analysis &Coordinating Center (LDACC)—Analysis Working Group; Statistical Methods groups—Analysis Working Group; Enhancing GTEx (eGTEx) groups; NIH Common Fund; NIH/NIC; NIH/NHLBI; NIH/NIMH; NIH/NIDA; Biospecimen Collection Source Site—NDR; Biospecimen Collection Source Site—RPCI; Biospecimen Core Resource—VARI; Brain Bank Repository—University of Miami Brain Endowment Bank; Leidos Biomedical—Project Management; ELSI Study; Genome Browser Data Integration &Visualization—EBI; Genome Browser Data Integration &Visualization—UCSC Genomics Institute, University of California Santa Cruz; Lead analysts; Laboratory, Data Analysis &Coordinating Center (LDACC); NIH program management; Biospecimen collection; Pathology; and eQTL manuscript working group (2017). Genetic effects on gene expression across human tissues. Nature 550, 204–213.

82. Saha, A., Kim, Y., Gewirtz, A.D.H., Jo, B., Gao, C., McDowell, I.C., Engelhardt, B.E., Battle, A.; and GTEx Consortium (2017). Co-expression networks reveal the tissue-specific regulation of transcription and splicing. Genome Res. 27, 1843–1858.

83. Li, M.J., Wang, L.Y., Xia, Z., Sham, P.C., and Wang, J. (2013). GWAS3D: Detecting human regulatory variants by integrative analysis of genome-wide associations, chromosome interactions and histone modifications. Nucleic Acids Res. 41, W150–8.

84. Sané, A.T., Seidman, E., Peretti, N., Klem, M., Delvin, E., Deslandres, C., Garofalo, C., Spahis, S., and Levy, E. (2017). Understanding chylomicron retention disease through Sar1b Gtpase gene disruption: insight from cell culture. Arterioscler. Thromb. Vasc. Biol. 37, 2243–2251.

85. Yuasa, K., Matsuda, T., and Tsuchi, A. (2011). Functional regulation of transient receptor potential canonical 7 by cGMP-dependent protein kinase Iα. Cell. Signal. 23, 1179–1187.

86. Ilegems, E., Iwatsuki, K., Kokrashvili, Z., Benard, O., Ninomiya, Y., and Margaolseke, R.E. (2010). REEP2 enhances sweet receptor function by recruitment to lipid rafts. J. Neurosci. 30, 13774–13783.
115. Yasuda, K., Miyake, K., Horikawa, Y., Hara, K., Osawa, H., Furuta, H., Hirotta, Y., Mori, H., Jonsson, A., Sato, Y., et al. (2008). Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat. Genet. 40, 1092–1097.

116. Unoki, H., Takahashi, A., Kawaguchi, T., Hara, K., Horitokshi, M., Andersen, G., Ng, D.P., Holmkvist, J., Borch-Johnsen, K., Jørgensen, T., et al. (2008). SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat. Genet. 40, 1098–1102.

117. Heard, E., Rougéolle, C., Arnaud, D., Avner, P., Allès, C.D., and Spector, D.L. (2001). Methylation of histone H3 at Lys-9 is an early mark on the X chromosome during X inactivation. Cell 107, 727–738.

118. Lai, Y.K., Lai, N.M., and Lee, S.W. (2017). Glucose-6-phosphate dehydrogenase deficiency and risk of diabetes: a systematic review and meta-analysis. Ann. Hematol. 96, 839–845.

119. Heymann, A.D., Cohen, Y., and Chodick, G. (2012). Glucose-6-phosphate dehydrogenase deficiency and type 2 diabetes. Diabetes Care 35, e58.

120. van der Wijst, M.G., and Rots, M.G. (2015). Mitochondrial epigenetics: an overlooked layer of regulation? Trends Genet. 31, 353–356.

121. Schleinitz, D., Kloeting, N., Lindgren, C.M., Breitfeld, J., Dietrich, A., Schon, M.R., Lohmann, T., Dreßler, M., Stumvoll, M., McCarthy, M.I., et al. (2014). Fat depot-specific mRNA expression of novel loci associated with waist-hip ratio. Int. J. Obes. 38, 120–125.

122. Meyre, D., Delplanque, J., Chèvre, J.C., Leccoeur, C., Lobhens, S., Gallina, S., Durand, E., Vatin, V., Degreve, E., Proença, C., et al. (2009). Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. Nat. Genet. 41, 157–159.

123. Bambace, C., Dahlman, I., Arner, P., and Kulytė, A. (2013). NPC1 in human white adipose tissue and obesity. BMC Endocr. Disord. 13, 5.

124. Jelinek, D., Castillo, J.J., and Garver, W.S. (2013). The C57BL/6J Niemann-Pick C1 mouse model with decreased gene expression of novel loci associated with waist-hip ratio. Int. J. Obes. 38, 120–125.

125. Wo, M., Szczepanowska, J., Pikula, S., Tylki-Szymaraska, A., Zablocki, K., and Bandorowicz-Pikuła, K. (2016). Mitochondrial dysfunction in fibroblasts derived from patients with Niemann-Pick type C disease. Arch. Biochem. Biophys. 593, 50–59.

126. Bernhard, F., Landgraf, K., Klötting, N., Berthold, A., Büttner, P., Friebe, D., Kiess, W., Kovacs, P., Blüher, M., and Körner, A. (2013). Functional relevance of genes implicated by obesity genome-wide association study signals for human adipocyte biology. Diabetologia 56, 311–322.

127. Buzaglo-Azriel, L., Kuperman, Y., Tsoory, M., Zaltzman, Y., Shachnai, L., Zaidman, S.L., Bassat, E., Michaelivici, L., Sarver, A., Tzahor, E., et al. (2016). Loss of muscle MTHC2 increases whole-body energy utilization and protects from diet-induced obesity. Cell Rep. 14, 1602–1610.

128. Li, Q., Wang, L., Tan, W., Peng, Z., Luo, Y., Zhang, Y., Zhang, G., Na, D., Jin, P., Shi, T., et al. (2011). Identification of C14qTNF-related protein 4 as a potential cytokine that stimulates the STAT3 and NF-kB pathways and promotes cell survival in human cancer cells. Cancer Lett. 308, 203–214.

129. Byerly, M.S., Petersen, P.S., Ramamurthy, S., Seldin, M.M., Lei, X., Provost, E., Wei, Z., Ronnett, G.V., and Wong, G.W. (2014). C1q/TNF-related protein 4 (CTRP4) is a unique secreted protein with two tandem C1q domains that functions in the hypothalamus to modulate food intake and body weight. J. Biol. Chem. 289, 4055–4069.

130. Sepe, M., Festa, L., Tolino, F., Bellucci, L., Sisto, L., Alfano, D., Ragno, P., Calabrò, V., de Francisca, V., La Mantia, G., and Pollice, A. (2011). A regulatory mechanism involving TBP-1/Tat-Binding Protein 1 and Akt/PKB in the control of cell proliferation. PLoS ONE 6, e22800.

131. Hinney, A., Albayrak, O., Antel, J., Volckmar, A.L., Sims, R., Chapman, J., Harold, D., Gerrish, A., Heid, I.M., Winkler, T.W., et al.; GERAD Consortium; IGAP Consortium; and GIANT Consortium (2013). Genetic variation at the CELF1 (CUGBP, elav-like family member 1 gene) locus is genome-wide associated with Alzheimer’s disease and obesity. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 165B, 283–293.

132. Ridler, C. (2016). Obesity: Inheritance via mitochondria. Nat. Rev. Endocrinol. 12, 497.

133. Semenkovich, C.F. (2017). We know more than we can tell about diabetes and vascular disease: The 2016 Edwin Bierman Award Lecture. Diabetes 66, 1735–1741.

134. Szendroedi, J., Phielix, E., and Roden, M. (2011). The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat. Rev. Endocrinol. 8, 92–103.

135. West, A.P., and Shadel, G.S. (2017). Mitochondrial DNA in innate immune responses and inflammatory pathology. Nat. Rev. Immunol. 17, 363–375.

136. Francis, J.W., Turn, R.E., Newman, L.E., Schiavon, C., and Kahn, R.A. (2016). Higher order signaling: ARL2 as regulator of both mitochondrial fusion and microtubule dynamics allows integration of 2 essential cell functions. Small GTPases 7, 188–196.

137. Castellana, S., Fusilli, C., Mazzoccoli, G., Biagini, T., Capocello, D., Carella, M., Vescovi, A.L., and Mazza, T. (2017). High-confidence assessment of functional impact of human mitochondrial non-synonymous genome variations by APOGEE. PLoS Comput. Biol. 13, e1005628.

138. Samuels, D.C., Carothers, A.D., Horton, R., and Chinnery, P.F. (2006). The power to detect disease associations with mitochondrial DNA haplogroups. Am. J. Hum. Genet. 78, 713–720.

139. Guo, Y., Lanktree, M.B., Taylor, K.C., Hakonarson, H., Lange, L.A., Keating, B.J.; and IBC 50K SNP array BMI Consortium (2013). Gene-centric meta-analyses of 108 912 individuals confirm known body mass index loci and reveal three novel signals. Hum. Mol. Genet. 22, 184–201.

140. Middelberg, R.P., Ferreira, M.A., Henders, A.K., Heath, A.C., Madden, P.A., Montgomery, G.W., Martin, N.G., and Whitfield, J.B. (2011). Genetic variants in LPL, OASL and TOMM40/APOE-C1-C2-C4 genes are associated with multiple cardiovascular-related traits. BMC Med. Genet. 12, 123.

141. Kraja, A.T., Chasman, D.I., North, K.E., Reiner, A.P., Yang, Y., Almasy, L., Collins, F.S., Peraldi, J., Johnson, A.D., et al.; Cross Consortia Pleiotropy Group; Cohorts for Heart and Aging Research in Global Populations; Global Lipids Genetics Consortium; and Meta-Analyses of Glucose; Insulin-related
traits Consortium; Global BPgen Consortium; ADIPOGen Consortium; Women's Genome Health Study; and Howard University Family Study (2014). Pleiotropic genes for metabolic syndrome and inflammation. Mol. Genet. Metab. 112, 317–338.

142. Pruim, R.J., Welch, R.P., Sanna, S., Teslovich, T.M., Chines, P.S., Gliedt, T.P., Boehnke, M., Abecasis, G.R., and Willer, C.J. (2010). LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 26, 2336–2337.